MicroRNA-targeted agents for treating heart disease

Inhibition of miR27b-5p using oligonucleic acid agents addresses the dysregulated mitochondrial ATP homeostasis in heart diseases, reducing pathological cardiac hypertrophy and endoreplication, and improving heart function.

CN112638475BActive Publication Date: 2024-12-06UNITED KINGDOM RESEARCH AND INNOVATION
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN201980055950.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-06-28
Filing Date
2019-06-28
Publication Date
2024-12-06
Estimated Expiration
2039-06-28

AI Technical Summary

Technical Problem

Current methods fail to address the underlying mechanism of pathological cardiac growth through endoreplication driven by dysregulated mitochondrial ATP homeostasis, particularly the role of miR27b-5p in heart diseases like hypertrophic cardiomyopathy and aortic stenosis.

Method used

Inhibition of miR27b-5p expression using oligonucleic acid agents that target and reduce the activity or expression of this microRNA, thereby altering pathological myocardial growth by redirecting mitochondrial ADP accumulation and de novo nucleotide biosynthesis.

Benefits of technology

This approach effectively inhibits pathological cardiac hypertrophy and endoreplication, reducing the number of multinucleated cardiomyocytes and improving heart function by targeting the HIF1α-MIR27B-ATP5A1-MTHFD1L axis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_5
    Figure SMS_5
  • Figure SMS_6
    Figure SMS_6
  • Figure SMS_7
    Figure SMS_7
Patent Text Reader

Abstract

The present invention relates to an oligonucleic acid reagent targeting microRNA miR27b-5p used in a method for treating or preventing heart disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention treats and prevents heart disease by administering oligonucleic acid agents that can regulate the activity or expression of microRNA. More specifically, the present invention provides a method for treating or preventing heart disease by inhibiting the expression and / or activity of microRNA miR27b-5p. Background Art

[0002] It is unclear by what mechanisms stress signals promote endoreplication and thereby DNA replication during the S phase of the cell cycle without subsequent mitosis and / or cytokinesis to increase the threshold of cell size. While analyses of cell cycle regulation, growth signaling pathways, and transcriptional and translational networks have provided insights into upstream control networks, more fundamental questions in underlying energetics by which these regulators are able to act remain unanswered. The energetic state of the cell determines not only ploidy (i.e., the number of chromosome sets in a cell) but also cell size and function to establish an environment that allows specific outputs that are co-selected by signaling cascades and transcriptional regulators to achieve specific growth or functional endpoints. Emerging evidence links dysregulation of ADP:ATP homeostasis to the development of hypertrophic cardiomyopathy (HCM) and aortic stenosis (AS) in humans. HCM and AS represent cardiac overgrowth phenotypes characterized by endoreplication resulting in polyploidy and multinucleation (cells with two or more nuclei), as well as the growth of pathological cardiomyocytes in an environment where mitochondrial ATP synthesis is inhibited. Paradoxically, energy-deficient cardiomyocytes, which display a reduced capacity to generate energy and cofactors through mitochondrial oxidation, are able to drive anabolic processes to support cardiac hypertrophy. Consistent with this, a major feature of mitochondrial myopathies is cardiac overgrowth.

[0003] Given that the metabolic hallmark of cardiac hypertrophy is reduced mitochondrial ATP synthesis, we set out to systematically analyze the expression of all subunits of the ATP synthase complex in biopsies from human HCM and AS patients. We identified ATP5A1 (encoding the α subunit of the ATP synthase catalytic F1 complex, which forms together with the β subunit, the catalytic domain around which the central stalk rotates to regenerate ATP from ADP and inorganic phosphate) as downregulated in HCM and AS biopsies. Mechanistically, we demonstrated that ATP5A1 inhibition was mediated by stress-dependent regulation of hypoxia-inducible factor (HIF)1α-driven induction of MIR27B. Inhibition of ATP5A1 inhibited mitochondrial ATP synthase activity, leading to the accumulation of intramitochondrial ADP, which is channeled and serves as a cofactor for MTHFD1L, a mitochondrially localized 1-carbon pathway rate-limiting enzyme that regulates formate and purine biosynthesis. Activation of MTHFD1L in cardiomyocytes by ADP accelerates de novo nucleotide synthesis and drives cardiomyocyte endoreplication and cell hypertrophy through parallel activation of AMPK-driven E2F. Accordingly, inactivation of MIR27B in vitro and in vivo in mice attenuates pre-existing heart failure caused by surgically mediated aortic stenosis (aortic arch coarctation (TAC)), whereas cardiac-specific expression of MIR27B results in spontaneous cardiac overgrowth. Analysis of downstream components ATP5A1 and MTHFD1L in mice further supports a central role for the HIF1α-MIR27B-ATP5A1-MTHFD1L axis in cardiac polyploidization and cell size control. Consistently, activation of this axis is associated with pathological cardiac hypertrophy in humans. These findings reveal a stress-dependent pathway that links dysregulated mitochondrial ATP homeostasis to pathophysiological endoreplication in cardiomyocytes, leading to multinucleation and morphological growth.

[0004] Since the inventors have identified cardiac metabolic endoreduplication as a heretofore unknown mechanism that indicates the progression of pathological growth in energy-deficient myocardium through overexpression of miR27b-5p, there is a need in the art for therapeutic methods that can inhibit the expression of miR27b-5p to prevent pathological growth through endoreduplication and de novo biosynthesis of nucleotides.

[0005] Based on the above prior art, the object of the present invention is to provide means and methods for treating heart disease (especially cardiomyopathy). This object is achieved by the subject matter of the claims of this specification.

[0006] manual

[0007] The present invention is based on the discovery that inhibition of miRNA miR27b-5p by administration of an oligonucleic acid agent (SEQ ID NO 001) can alter pathological myocardial growth by utilizing regulatory factors such as ATP synthase, which drives mitochondrial ADP accumulation and redirects it to methylenetetrahydrofolate dehydrogenase 1L (MTHFD1L) and de novo nucleotide biosynthesis.

[0008] In the context of the present invention, the term "miRNA" relates to immature, premature and mature miRNA.

[0009] The stem-loop sequence of miRNA27b has two mature subspecies, namely miRNA27b-3p and miRNA27b-5p.

[0010] In the context of the present invention, "capable of forming a hybrid" relates to a sequence that can selectively bind to its target sequence under cytosolic conditions of a mammalian cell. Such hybridizing sequences may be continuous reverse complements to the target sequence, or may contain gaps, mismatches or other unmatched nucleotides. The minimum length of a sequence capable of forming a hybrid depends on its composition, with C or G nucleotides contributing more to the binding energy and backbone chemistry than A or T / U nucleotides.

[0011] In the context of this specification, the term "oligonucleic acid agent" refers to an oligonucleotide that can specifically bind to miR27b-5p and cause a significant reduction in the physiological effects of miR27b-5p. Embodiments of the oligonucleic acid agent of the present invention are antisense oligomers made of DNA (having a phosphorothioate modified bond in its main chain), ribonucleotide oligomers, RNA containing bridged or locked nucleotides, in particular, wherein the ribose rings are connected by a methylene bridge between the 2'-O and 4'-C atoms, and the RNA has a phosphorothioate modified bond in its main chain, or any mixture consisting of deoxyribonucleotides and ribonucleotide bases as an oligomer.

[0012] In the context of this specification, the term "antisense oligonucleotide" or "oligonucleotide agent" refers to any oligonucleotide that can specifically bind to miR27b-5p and cause a significant reduction in the physiological effects of miR27b-5p. Embodiments of the antisense oligonucleotides of the present invention are antisense oligomers made of DNA (having phosphorothioate modified bonds in its main chain), ribonucleotide oligomers, RNA containing bridged or locked nucleotides, in particular, wherein the ribose rings are linked by a methylene bridge between the 2'-O and 4'-C atoms, and the RNA has a phosphorothioate modified bond in its main chain, or any mixture consisting of deoxyribonucleotides and ribonucleotide bases as an oligomer.

[0013] The terms "oligonucleic acid agent" and "antisense oligonucleotide" or "oligonucleotide agent" are used interchangeably in this specification.

[0014] In certain embodiments, the antisense oligonucleotides of the present invention include analogs of nucleic acids, such as phosphates, 2'O-methylthiophosphates, peptide nucleic acids (PNA; N-(2-aminoethyl)-glycine units linked by peptide bonds, with the nucleobase attached to the alpha carbon of glycine) or locked nucleic acids (LNA; RNA structural units bridged by 2'O, 4'C methylene groups). The antisense sequence may be composed in part of any of the above-mentioned nucleic acid analogs, with the remaining nucleotides being "natural" ribonucleotides present in nature, or may be a mixture of different analogs, or may be composed entirely of one analog.

[0015] The term "gapmer" is used in its known sense in the field of molecular biology and refers to an antisense oligonucleotide complementary to its target sequence, which comprises a central block of deoxyribonucleotide oligomers flanked by short ribonucleotide oligomers. The flanking ribonucleotide oligomers consist of nuclease and protease resistant ribonucleotides. In certain embodiments, the nuclease and protease resistant ribonucleotides comprise 2'-O modified ribonucleotides, particularly bridging nucleic acids having a bridge between the 2'-O and 4'-C of the ribose moiety.

[0016] In the context of the present invention, "nucleotide" is a structural unit of a nucleic acid or a nucleic acid analog, whose oligomers are able to form selective hybrids with miRNA oligomers based on base pairing. In this article, the term "nucleotide" includes classical ribonucleotide structural units, i.e., adenosine, guanosine, uridine (and ribothymosin), cytidine, and classical deoxyribonucleotides, i.e., deoxyadenosine, deoxyguanosine, thymidine, deoxyuridine and deoxycytidine. It also includes analogs of nucleic acids, such as phosphates, 2'O-methylthiophosphates, peptide nucleic acids (PNA; N-(2-aminoethyl)-glycine units linked by peptide bonds, whose nucleobases are attached to the α carbon of glycine) or locked nucleic acids (LNA; RNA structural units bridged by 2'O, 4'C methylene groups). The hybridization sequence can be composed of any of the above nucleotides or a mixture thereof.

[0017] In the context of this specification, the terms "sequence identity" and "sequence identity percentage" refer to the value determined by comparing the sequences of two comparisons. The sequence alignment method for comparison is well known in the art. The comparison of the sequence for comparison can be carried out by local homology algorithm (Smith and Waterman, Adv.Appl.Math.2:482 (1981)), global alignment algorithm (Needleman and Wunsch, J.Mol.Biol.48:443 (1970)), similarity search method (Pearson and Lipman, Proc.Nat.Acad.Sci.85:2444 (1988)) or computerized tools of these algorithms, including but not limited to CLUSTAL, GAP, BESTFIT, BLAST, FASTA and TFASTA. The software for performing BLAST analysis is publicly available, for example, obtained through the National Center for Biotechnology Information website (http: / / blast.ncbi.nlm.nih.gov / ). One embodiment for comparing amino acid sequences is the BLASTP algorithm using default settings: Expected threshold: 10; Word length: 3; Maximum matches in query range: 0; Matrix: BLOSUM62; Gap cost: 11 for presence, 1 for extension; Component adjustment: Conditional composite score matrix adjustment. One such embodiment for comparing nucleic acid sequences is the BLASTN algorithm using default settings: Expected threshold: 10; Word length: 28; Maximum matches in query range: 0; Match / mismatch score: 1-2; Gap cost: linear. Unless otherwise indicated, the sequence identity values ​​provided herein refer to the values ​​obtained using the BLAST suite of programs (Altschul et al., J. Mol. Biol. 215: 403-410 (1990)), wherein the default parameters determined above were used for protein and nucleic acid comparisons, respectively. DETAILED DESCRIPTION

[0018] The first aspect of the present invention provides an oligonucleic acid agent targeting microRNA miR27b-5p for use in a method for treating or preventing heart disease.

[0019] In other words, the oligonucleic acid reagent of the present invention is directed against miRNA miR27b-5p (SEQ ID NO 002) or is capable of forming a hybrid with miRNA miR27b-5p (SEQ ID NO 002).

[0020] In certain embodiments, the oligonucleic acid agent is directed against the miR27b-5p miRNA in its mature form.

[0021] In certain embodiments, when the oligonucleic acid agent is introduced into a mammalian cell, the oligonucleic acid agent is capable of reducing the level of miR27b-5p miRNA in the cell (expressed as a percentage) by at least 10% to 20%, at least 30% to 40%, at least 50% to 60%, at least 70% to 80%, at least 90% to 98% or at least 99%. In certain embodiments, the oligonucleic acid agent used in the method for treating or preventing heart disease comprises or consists essentially of the sequence ACC AAT CAG CTAAGCT (SEQ ID NO 001).

[0022] The oligonucleic acid reagents of the present invention are defined by their sequences; however, those skilled in the art understand that sufficient binding specificity can be obtained to achieve the effects of the present invention by exchanging one or two positions, particularly while increasing binding to mRNA by introducing nucleotide analogs.

[0023] In certain embodiments, the oligonucleic acid reagent comprises a sequence that hybridizes to miR27b-5p. The reagent sequence is at least 95% identical to SEQ ID 001, particularly 96%, 97%, 98%, 99% or 100% identical. In certain embodiments, the hybridization sequence comprises deoxynucleotides, phosphorothioate deoxynucleotides, LNA and / or PNA nucleotides or mixtures thereof.

[0024] Antisense nucleic acids composed partially or entirely of nucleoside analogs

[0025] In certain embodiments, the oligonucleic acid agent is an antisense oligonucleotide.

[0026] In certain embodiments, an oligonucleic acid agent comprises or consists essentially of an LNA portion and comprises about 20 nucleotides or fewer.

[0027] In certain embodiments, the oligonucleic acid agent consists essentially of an LNA portion and is described by the sequence ACC AAT CAGCTA AGC T (SEQ ID NO 008). In a specific embodiment, the nucleoside analog of SEQ ID NO 008 is linked via a phosphate. In a specific embodiment, the nucleoside analog of SEQ ID NO 008 is linked via a phosphorothioate.

[0028] In certain embodiments, the oligonucleic acid agent used in the methods of treating or preventing heart disease comprises or consists essentially of one or more peptide nucleic acid (PNA) moieties.

[0029] In certain embodiments, the present invention includes a method of treating or preventing heart disease in a subject in need thereof, the method comprising administering to the subject an oligonucleotide agent directed against miRNA miR27b-5p.

[0030] Sequence-specific chemically modified oligonucleotides can inhibit miRNA miR27b-5p. In certain embodiments, the oligonucleic acid reagents of the present invention may include locked nucleic acids (LNA), wherein the ribose moiety of the nucleic acid is modified by an additional bridge connecting 2' oxygen and 4' carbon, which locks the ribose in a 3' internal conformation. Similarly, the oligonucleic acid reagents of the present invention may include a PNA moiety. LNA and PNA have higher binding energy with base-matched DNA or RNA, resulting in tighter binding. This binding may increase antisense inhibition of complementary miR27b-5p miRNA targets. In certain embodiments, the oligonucleic acid reagents of the present invention may include phosphonate, phosphorothioate or phosphate-phosphate backbone modifications. In certain embodiments, the oligonucleic acid reagents of the present invention may include ribonucleotides. Alternatively, the oligonucleic acid reagents of the present invention may include deoxyribonucleotides. In certain embodiments, the hybridization sequence of the oligonucleic acid reagents includes ribonucleotides, deoxynucleotides, phosphorothioate deoxynucleotides, phosphorothioate ribonucleotides and / or 2'-O-methyl modified phosphorothioate ribonucleotides. In certain embodiments, the oligonucleic acid reagent comprises ribonucleotides and deoxyribonucleotides, particularly modified ribonucleotides and modified deoxyribonucleotides. A non-limiting example of modification of deoxyribonucleotides and ribonucleotides is a phosphorothioate modified bond in the oligonucleotide backbone. A non-limiting example of modification of ribonucleotides is a 2'-O to 4'-C bridge. In certain embodiments, the 2 / 4C bridge is a five-membered, six-membered or seven-membered bridge structure.

[0031] Antisense gapmer

[0032] In certain embodiments, the oligonucleic acid reagent is a gap polymer characterized by a central DNA block, the sequence of the central DNA block is complementary to the miR27b-5p miRNA, and the two sides (5' and 3') of the central DNA block are flanked by anti-nuclease LNA sequences that are also complementary to the miR27b-5p miRNA. The central DNA block contains an RNase H activation domain, i.e., it is the part that causes hydrolysis of the target DNA. In certain embodiments, the flanking LNAs are fully phosphorothioated.

[0033] In certain embodiments, the oligonucleic acid agent comprises 12-20 nucleotides. In certain specific embodiments, the oligonucleic acid agent comprises 14-16 nucleotides.

[0034] In certain embodiments, the hybridizing sequence of the oligonucleic acid reagent obtained according to the present invention comprises 14, 15 or 16 nucleotides.

[0035] In certain embodiments, the central deoxyribonucleotide oligomer block of the gapmer comprises at least 5 deoxyribonucleotides. In certain embodiments, the central deoxyribonucleotide oligomer block of the gapmer comprises 5-10 deoxyribonucleosides linked by phosphate bonds or phosphorothioate bonds.

[0036] In certain embodiments, the central deoxyribonucleotide oligomer block of the gapmer comprises a phosphate backbone between deoxyribonucleosides.

[0037] In certain embodiments, the oligonucleic acid reagent comprises or consists essentially of a central block of deoxyribonucleotides (5-10) linked by phosphate bonds, and the two sides of the central block are flanked by 2'-O modified ribonucleotides or PNA oligomers. In certain embodiments, the oligonucleic acid reagent comprises or consists essentially of a central block of deoxyribonucleosides (5-10) flanked by LNA nucleoside analogs. In certain specific embodiments, the LNA nucleoside analogs are linked by phosphorothioate moieties.

[0038] In certain embodiments, the oligonucleic acid agent of the present invention comprises the sequence ACCA-atcagcta-AGCT (SEQ ID NO 005) or is essentially composed thereof, wherein capital letters represent nucleoside analogs (particularly LNA, more particularly LNA linked by thiophosphate), lowercase letters represent DNA nucleosides linked by phosphate, and the connection between the nucleoside analog and the DNA nucleoside is achieved by phosphate and thiophosphate.

[0039] RNAi / siRNA / shRNA

[0040] In certain embodiments, the oligonucleic acid agent is a ribonucleic acid agent, particularly siRNA or shRNA.

[0041] In the context of this specification, RNA interference (RNAi) agents refer to ribonucleotide oligomers that cause degradation of their enhancer RNA (eRNA) target sequences.

[0042] In certain embodiments, the RNAi agent of the present invention comprises or consists of:

[0043] - a single-stranded or double-stranded interfering RNA oligomer or a precursor thereof, which comprises a sequence segment complementary to a targeted enhancer RNA molecule; or

[0044] - Single-stranded or double-stranded antisense ribonucleic acid or deoxyribonucleic acid comprising a sequence segment complementary to the targeted enhancer RNA molecule.

[0045] In certain embodiments, the sequence segment complementary to the targeting enhancer RNA molecule is a contiguous sequence segment of 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 nucleotides in length.

[0046] In certain embodiments, the RNAi agents of the present invention include but are not limited to small interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA and non-coding RNA, etc., morpholino (phosphodiamidate morpholino oligomer) and Dicer substrate siRNA (DsiRNA, which is cut into 21-23 base duplexes with 2-base 3'-overhangs by RNAse III class endoribonuclease Dicer), UsiRNA (UsiRNA is a double-stranded siRNA modified with a non-nucleotide acyclic monomer, called "unlocked nucleobase analog (UNA)", in which the bond between two adjacent carbon atoms of ribose is removed), including rxRNA TM (RXi Pharmaceuticals, Westborough, MA, USA).

[0047] In some embodiments, the RNAi agent of the invention comprises an analog of a nucleic acid, such as a phosphate, 2'O-methylphosphorothioate, a peptide nucleic acid (PNA; N-(2-aminoethyl)-glycine units linked by peptide bonds, with the nucleobase attached to the alpha carbon of glycine) or a locked nucleic acid (LNA; RNA structural units bridged by 2'O, 4'C methylene groups). The hybridization sequence may be composed in part of any of the above nucleotides, with the remaining nucleotides being "natural" ribonucleotides occurring in nature, or may be a mixture of different analogs, or may be composed entirely of one analog.

[0048] In certain embodiments, the oligonucleic acid agents are conjugated to or encapsulated by nanoparticles, viruses, and lipid complexes.

[0049] In certain embodiments, the oligonucleic acid agent is a gapmer comprising a central deoxyribonucleotide oligomer block, wherein the block is flanked on both sides (5' and 3') by nuclease-resistant ribonucleotide analogs.

[0050] Within the scope of the present invention there is provided a method for treating or preventing a heart disease in a patient in need thereof, the method comprising administering to the patient an oligonucleic acid agent obtained according to the present invention.

[0051] Similarly, a dosage form for preventing or treating heart disease is provided, which comprises the oligonucleic acid agent obtained according to the present invention.

[0052] The dosage form may be administered enterally, for example, nasally, buccally, rectally, transdermally or orally, or as an inhalant or suppository. Alternatively, it may be administered parenterally, for example, in the form of subcutaneous, intravenous, intrahepatic or intramuscular injection. Optionally, a pharmaceutically acceptable carrier and / or excipient may be present.

[0053] In certain embodiments, the amount of the oligonucleic acid agent sufficient to reduce miR27b-5p miRNA expression within a cellular environment is 1 nmol or less, 200 pmol or less, 100 pmol or less, 50 pmol or less, 20 pmol or less, 10 pmol or less, 5 pmol or less, 2 pmol or less, or 1 pmol or less.

[0054] sequence

[0055] SEQ ID NO 001 (miR27b-5p targeting sequence; 5'-3', and nucleotide chemistry):

[0056] ACC AAT CAG CTA AGC T

[0057] SEQ ID NO 002 (miR27b-5p)

[0058] GCAGAAC UUAGCCACUGU GAA

[0059] SEQ ID NO 003 (AAV9-fl / fl-shMthfd11; positive sense):

[0060] TGAATGGTGTCAGAGAATTTTTCAAGAGAAAATTCTCTGACACCATTCTTTTTTC

[0061] SEQ ID NO 004 (AAV9-fl / fl-shMthfd11; antisense):

[0062] TCGAGAAAAAAGAATGGTGTCAGAGAATTTTCTCTTGAAAAATTCTCTGACACCATTCA

[0063] SEQ ID NO 005 ACCA-atcagcta-AGCT (upper case: nucleoside analog, in particular LNA linked via phosphorothioate; lower case: DNA; border: phosphate or phosphorothioate)

[0064] SEQ ID NO 006 (forward primer sequence; mir27b): GCATGCTGATTTGTGACTTGAG-3'

[0065] SEQ ID NO 007 (reverse primer sequence; mir27b): 5-CCTCTGTTCTCCAAACTGCAG-3'

[0066] SEQ ID NO 008: (miR27b-5p targeting sequence; 5'-3', LNA):

[0067] ACC AAT CAG CTA AGC T

[0068] Alternatives of single separable features are presented herein as "embodiments"; it should be understood that these alternatives can be freely combined to form discrete embodiments of the invention disclosed herein.

[0069] The present invention is further illustrated by the following examples and figures, from which further embodiments and advantages can be derived. These examples are intended to illustrate the present invention, but not to limit its scope. Sequence Listing <110> Genome Biology UG <120> MicroRNA-targeted agents for the treatment of heart disease <130> tar103wo <160> 8 <170> PatentIn Version 3.5 <210> 1 <211> 16 <212> DNA <213> Artificial sequence <220> <223> Oligonucleotide Reagents <400> 1 accaatcagc taagct 16 <210> 2 <211> twenty one <212> RNA <213> Homo sapiens <400> 2 gcagaacuua gccacuguga a 21 <210> 3 <211> 55 <212> DNA <213> Artificial sequence <220> <223> Oligonucleotide Reagents <400> 3 tgaatggtgt cagagaattt ttcaagagaa aattctctga caccattctt ttttc 55 <210> 4 <211> 59 <212> DNA <213> Artificial sequence <220> <223> Oligonucleotide Reagents <400> 4 tcgagaaaaa agaatggtgt cagagaattt tctcttgaaa aattctctga caccattca 59 <210> 5 <211> 16 <212> DNA <213> Artificial sequence <220> <223> Oligonucleotide Reagents <400> 5 accaatcagc taagct 16 <210> 6 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> Primers <400> 6 gcatgctgat ttgtgacttg ag 22 <210> 7 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Primers <400> 7 cctctgttct ccaaactgca g 21 <210> 8 <211> 16 <212> DNA <213> Artificial sequence <220> <223> Oligonucleotide Reagents <400> 8 accaatcagc taagct 16 BRIEF DESCRIPTION OF THE DRAWINGS

[0070] Figure 1 A-1B shows the control of endoreplication and multinucleation in pathological growth by F1F0 ATP synthase. Expression of genes encoding ATP synthase subunits and markers of cardiac hypertrophy and dysfunction (NPPA and NPPB) in left ventricular biopsies of patients with hypertrophic cardiomyopathy (HCM) and aortic stenosis (AS) compared with healthy controls and in ventricular biopsies of mice with aortic arch constriction (TAC) compared with sham-operated animals. Interventricular septal diameter (IVSD; d) and left ventricular posterior wall diastolic diameter (LVPWD; d) obtained by echocardiography, as well as fractional shortening (%FS) and ejection fraction (%EF) of animals with TAC or sham surgery.

[0071] Figure 1 C-1D shows left ventricular biopsies from patients with HCM and aortic stenosis and healthy controls (c) or sham- and TAC-operated mice (d), which were evaluated by immunoblotting for the expression of the indicated proteins.

[0072] Figure 1 E-1F shows the ADP / ATP ratio in ventricular biopsies of patients with HCM and aortic stenosis relative to healthy controls (e), and in ventricular biopsies of TAC-operated mice relative to sham-operated animals (f).

[0073] Figure 1 G shows longitudinal sections of the left ventricle of patients with aortic stenosis (AS) (n=3) and hypertrophic cardiomyopathy (HCM) (n=3) and healthy controls (n=3), stained to visualize DAPI (blue), laminin (green), and α-actin (red), and imaged by confocal microscopy.

[0074] Figure 1 H shows that Figure 1 Heart sections stained in G were assessed for the percentage of mononuclear, binucleated, or multinucleated myocytes.

[0075] Figure 1 I shows longitudinal sections of left ventricles of sham-operated (n=3) and TAC-operated (n=3) mice, stained to visualize DAPI (blue), laminin (green), and α-actin (red), and imaged by confocal microscopy.

[0076] Figure 1J shows that the ratio of mononuclear and multinucleated myocytes was assessed in cardiac sections stained as in (i) (2 sections from each heart were analyzed and 2 areas from each section were used for quantification; a total of 3 hearts were analyzed per group).

[0077] Figure 1 K shows a schematic diagram of AAV9-fl / fl-shAtp5a1 virus before and after Cre-mediated recombination (left) and the experimental timeline (right).

[0078] Figure 1 L shows the use of antibodies against the indicated proteins to detect the expression of Mlc2v-cre cells transduced with AAV9-fl / fl-shAtp5a1. + and Mlc2v-cre - Immunoblots of mouse ventricular lysates.

[0079] Figure 1 M shows Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1 11 weeks after AAV9 injection. + and Mlc2v-cre - ADP / ATP ratio measured in left ventricle samples from mice.

[0080] Figure 1 N shows Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1 + (n=3) and Mlc2v-cre - (n=3) Longitudinal sections of left ventricles of mice stained to visualize DAPI (blue), laminin (green), and α-actin (red) and imaged by confocal microscopy.

[0081] Figure 1 O shows that Figure 1 Heart sections stained in N were evaluated for the ratio of mono-, binucleated, or multi-nucleated myocytes.

[0082] Figure 1 P shows Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1 11 weeks after AAV9 injection. + and Mlc2v-cre - Representative images of the left ventricle of a mouse.

[0083] Figure 1 Q shows Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1 11 weeks after AAV9 injection + and Mlc2v-cre -Representative images of H&E-stained tissue sections from mice.

[0084] Figure 1 R-1S shows Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1 11 weeks after AAV9 injection + and Mlc2v-cre - Left ventricular weight / body weight (LVW / BW) (R) and ejection fraction (S) of mice.

[0085] Figure 2 A shows the expression of MIR27B in patients with hypertrophic cardiomyopathy (HCM) or aortic stenosis (AS).

[0086] Figure 2 B shows a schematic timeline of the experiment with Mlc2v-cre mice transduced with AAV9-fl / fl-mir27b.

[0087] Figure 2 C shows Mlc2v-cre injected with AAV9-fl / fl-mir27b virus + and Mlc2v-cre - Representative images of the left ventricle of a mouse.

[0088] Figure 2 D shows Mlc2v-cre transduced with AAV9-fl / fl-mir27b virus + and Mlc2v-cre - Representative images of H&E-stained tissue sections from mice.

[0089] Figure 2 E-2F shows Mlc2v-cre injected with AAV9-fl / fl-mir27b virus + and Mlc2v-cre - LVW / BW (e) and ejection fraction (f) of mice.

[0090] Figure 2 G shows mature miR27b-5p and miR27b-3p in Mlc2v-cre injected with AAV9-fl / fl-mir27b virus + and Mlc2v-cre - Relative expression in mice.

[0091] Figure 2 H shows the use of antibodies against the indicated proteins from Figure 2 Mlc2v-cre transduced in CG + and Mlc2v-cre -Immunoblots of mouse ventricular lysates. Figure 2 I shows Mlc2v-cre transduced with AAV9-fl / fl-mir27b + (n=3) and Mlc2v-cre - (n=3) Longitudinal sections of left ventricles of mice stained to visualize DAPI (blue), laminin (green), and α-actin (red) and imaged by confocal microscopy.

[0092] Figure 2 J shows that Figure 2 Heart sections stained in I were evaluated for the ratio of mononuclear and multinucleated myocytes.

[0093] Figure 2 K shows a schematic diagram of antagonist studies in sham- and TAC-operated mice. Baseline echocardiographic measurements were performed on day 5, sham or TAC surgery was performed on day 0, and scrRNA and miR27b-5p LNA were administered intraperitoneally (ip) on days 49-52 after surgery and monitored by echocardiography at the indicated time points.

[0094] Figure 2 L-2M shows the left ventricle ( Figure 2 L) and H&E staining ( Figure 2 M) Representative images of tissue sections.

[0095] Figure 2 N-2P shows LVW / BW ( Figure 2 N), left ventricular end-systolic diameter (LVID; s) ( Figure 2 O) and ejection fraction ( Figure 2 P) longitudinal monitoring results.

[0096] Figure 2 Q-2T shows mature miR27b-5p ( Figure 2 Q), miR27b-3p( Figure 2 R), Nppa and Nppb ( Figure 2 S) and Atp5a1 mRNA ( Figure 2 T) Relative expression in C57BL / 6J mice treated with scrLNA or miR27b-5p LNA and subjected to sham or TAC surgery by qPCR.

[0097] Figure 2U shows immunoblots using antibodies against the indicated proteins from ventricular lysates of C57BL / 6J mice that were sham- and TAC-operated and treated with scrRNA or miR27b-5p LNA.

[0098] Figure 2 V shows longitudinal sections of the left ventricle of sham- and TAC-operated mice, in which scrLNA or miR27b-5pLNA was stained to visualize DAPI (blue), laminin (green), and α-actin (red), and imaged by confocal microscopy.

[0099] Figure 2 W shows that the ratio of mononuclear and multinucleated myocytes was assessed in cardiac sections stained as in (v).

[0100] Figure 2 X shows Kaplan-Meier survival curves comparing mortality between sham-operated or TAC-operated mice and mice treated with scrLNA or miR27b-5p LNA. No mortality was observed in sham-operated animals.

[0101] FIG3A is a schematic diagram of the de novo purine biosynthetic pathway showing the contributions of glycolysis and 1-carbon metabolism.

[0102] Figure 3B shows the relative amounts of formate in NRCs transduced and treated as indicated.

[0103] FIG. 3C shows the relative mitochondrial ADP / ATP ratios in NRCs transduced and treated as indicated.

[0104] Figure 3D shows a heat map of relative metabolite abundance in NRCs transduced and treated as indicated. The metabolites depicted met "log2(fold change)>0.5" in at least one treatment group (n=4 biological replicates per group) and met "p-value<0.01" after adjustment compared to the corresponding control treatment group.

[0105] FIG3E shows the incorporation of nucleic acids into NRCs transduced and treated as indicated. 14 C] glucose, 14 C]serine and [ 14 C] glycine derived [ 14 C] relative amount of carbon.

[0106] Figure 4 A-4F shows that NRCs transduced and treated as indicated were stained with propidium iodide (PI) and their ploidy was assessed by flow cytometry combined with imaging (a, c, e) and their multinucleation was quantified from images (b, d, f).

[0107] Figure 4 G-4I shows the incorporation of [ 3 Data are expressed as incorporated radioactivity relative to the control NRC (set to 1.0).

[0108] Figure 5 A shows a schematic timeline of the experiments with Mlc2v-cre mice that underwent sham or TAC surgery and were transduced with AAV9-fl / fl-shMthfd11.

[0109] Figure 5 B shows Mlc2v-cre cells after sham surgery or TAC surgery and injection of AAV9-fl / fl-shMthfd1l virus. + and Mlc2v-cre - Longitudinal section of the left ventricle of a mouse, stained to visualize DAPI (blue), laminin (green), and α-actin (red), and imaged by confocal microscopy (3 sections from each heart were analyzed, and 2-4 fields from each section were imaged, and representative z-stacks are shown; 3 hearts were analyzed per group). Arrows indicate nucleation of cardiomyocytes.

[0110] Figure 5 C shows the ratio of mononuclear and multinucleated myocytes was assessed in cardiac sections stained as in (b).

[0111] Figure 5 D shows Mlc2v-cre cells after sham surgery or TAC surgery and injection of AAV9-fl / fl-shMthfd1l virus. + and Mlc2v-cre - Representative images of the left ventricle of a mouse.

[0112] Figure 5 E shows Mlc2v-cre cells that underwent sham surgery or TAC surgery and were injected with AAV9-fl / fl-shMthfd1l virus. + and Mlc2v-cre - Representative images of H&E-stained tissue sections from mice.

[0113] Figure 5 F-5G shows Mlc2v-cre cells after sham surgery or TAC surgery and injection with AAV9-fl / fl-shMthfd1l virus. + and Mlc2v-cre - LVW / BW (f) and ejection fraction (g) of mice.

[0114] Figure 5H shows the expression of antibodies against the indicated proteins from sham- or TAC-operated Mlc2v-cre cells transduced as in (bg). + and Mlc2v-cre - Immunoblots of mouse ventricular lysates.

[0115] Figure 5 I shows a schematic timeline of the experiment of Mlc2v-cre mice co-transduced with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd11.

[0116] Figure 5 J shows Mlc2v-cre co-transduced with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l + (n=3) and Mlc2v-cre - (n=3) Longitudinal sections of left ventricles of mice stained to visualize DAPI (blue), laminin (green), and α-actin (red) and imaged by confocal microscopy.

[0117] Figure 5 K shows the ratio of mononuclear and multinucleated myocytes was assessed in cardiac sections stained as in (j).

[0118] Figure 5 L shows Mlc2v-cre co-transduced with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l + and Mlc2v-cre - Representative images of the left ventricle of a mouse. Figure 5 M shows Mlc2v-cre co-transduced with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l + and Mlc2v-cre - Representative images of H&E-stained tissue sections from mice.

[0119] Figure 5 N-5O shows Mlc2v-cre co-transduced with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l + and Mlc2v-cre - LVW / BW (n) and ejection fraction (o) of mice.

[0120] Figure 5 P shows the Mlc2v-cre transduced from jp using antibodies against the indicated proteins +and Mlc2v-cre - Immunoblots of mouse ventricular lysates.

[0121] Figure 6 A shows immunoblot of NRC ectopically expressing a constitutively active form of AMPKαl using antibodies against the indicated proteins.

[0122] Figure 6 B shows immunoprecipitation (IP) of NRC ectopically expressing a constitutively active form of AMPKα1 using control IgG or anti-AMPKα antibody. IPs were blotted with p-AMPKα and p-Rb antibodies.

[0123] Figure 6 C shows immunoblots of NRCs ectopically expressing HIF1αΔODD and treated with DMSO or AMPK inhibitor Compound C (CC) using antibodies against the indicated proteins.

[0124] Figure 6 D shows immunoprecipitation of NRC ectopically expressing HIF1αΔODD and treated with DMSO or the AMPK inhibitor CC using control IgG or anti-AMPKα antibody. IPs were blotted with p-AMPKα and p-Rb antibodies.

[0125] Figure 6 E shows immunoblots using antibodies against p-Rb and total Rb from ventricular lysates of mice that were sham- or TAC-operated and treated with scrRNA or miR27b-5p LNA.

[0126] Figure 6 F shows the use of antibodies against p-Rb and total Rb to extract the Mlc2v-cre injected with AAV9-fl / fl-mir27b virus. + and Mlc2v-cre - Immunoblots of mouse ventricular lysates.

[0127] Figure 6 G shows the use of antibodies against p-Rb and total Rb to extract the Mlc2v-cre cells injected with AAV9-fl / fl-shAtp5a1 virus. + and Mlc2v-cre - Immunoblots of mouse ventricular lysates.

[0128] Figure 6 H shows the use of antibodies against p-Rb and total Rb to isolate Mlc2v-cre cells from sham-operated or TAC-operated mice injected with AAV9-fl / fl-shMthfd1l virus. + and Mlc2v-cre- Immunoblots of mouse ventricular lysates.

[0129] Figure 6 I shows the use of antibodies against p-Rb and total Rb to isolate Mlc2v-cre co-transduced with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd11. + and Mlc2v-cre - Immunoblots of mouse ventricular lysates.

[0130] Figure 6 J shows immunoblots of ventricular lysates from patients with HCM and aortic stenosis and healthy controls using antibodies against p-Rb and total Rb. Figure 6 K shows a heat map of the relative expression of the indicated genes in ventricular lysates of mice that were sham-operated or TAC-operated and treated with scrLNA or miR27b-5p LNA. Figure 6 L shows the expression of the indicated genes in Mlc2v-cre injected with AAV9-fl / fl-mir27b + and Mlc2v-cre - Heat map of relative expression in mouse ventricular lysates.

[0131] Figure 6 M shows the expression of the indicated genes in Mlc2v-cre after sham surgery or TAC surgery and injection with AAV9-fl / fl-shMthfd1l virus + and Mlc2v-cre - Heat map of relative expression in mouse ventricular lysates.

[0132] Figure 6 N shows a heat map of the relative expression of the indicated genes in ventricular lysates of patients with HCM and aortic stenosis and healthy controls.

[0133] Figure 6 O shows transfection of the E2F luciferase reporter gene in NRCs infected and treated as indicated. Data were normalized to infected control NRCs (set to 1.0). Figure 6 P shows transfection of the E2F luciferase reporter gene in NRCs infected as indicated. Data were normalized to infected control NRCs (set to 1.0).

[0134] Figure 6Q shows the mechanism of action of F1F0 ATP synthase function in cardiac ploidy and growth control. Pathological stress leads to the stabilization and accumulation of HIF1α and HIF1α-dependent induction of glycolytic genes and the microRNA MIR27B. In turn, MIR27B binds to the 3'UTR of the α subunit of the F1F0 ATP synthase (ATP5A1), thereby targeting it for degradation. Due to the inhibition of F1F0 ATP synthase, the ADP / ATP ratio in the mitochondrial matrix increases, which on the one hand activates the energy sensor AMPK. pAMPK then hyperphosphorylates Rb, leading to the release of the transcription factor E2F and the induction of cell cycle protein and CDK expression. On the other hand, the accumulated mitochondrial ADP is redirected to MTHFD1L, an enzyme involved in mitochondrial 1-carbon metabolism, which uses ADP as a cofactor to catalyze the conversion of CHO-THF to formate. Formate (especially formate derived from serine) is used as a 1-carbon donor in the de novo synthesis of purines. Increased de novo formation of purines as substrates for nucleic acid synthesis and induction of cyclins and CDKs promote DNA replication, multinucleation, and cardiac growth. CHO-THF denotes formyltetrahydrofolate, CH2-THF denotes methylenetetrahydrofolate, and 3-PG denotes 3-phosphoglycerate.

[0135] Figure 7 a shows Figure 1 a Pearson correlation coefficients of ATP synthase subunit genes and NPPB expression shown in (left panel) (n=4 for healthy controls; n=10 for AS patients; n=11 for HCM patients).

[0136] Figure 7 b shows the quantification results of ATP levels in ventricular lysates of sham- and TAC-operated animals (n = 5 for sham-operated animals; n = 6 for TAC-operated animals; data shown are mean ± SEM; *** p < 0.001; two-tailed unpaired t test).

[0137] Figure 7 c shows left ventricular sections of patients with HCM (n=3) and aortic stenosis (n=3) and healthy controls (n=3) stained with hematoxylin and eosin (H&E) and imaged by light microscopy (2 sections per heart (2 areas per section) were examined and representative areas are shown). Scale bar, 200 μm. Figure 7 d shows left ventricular sections of sham-operated (n=3) and TAC-operated (n=3) mice stained with H&E and imaged by light microscopy (3 sections per heart (3-5 fields per section) were examined, and representative fields are shown). Scale bar, 200 μm.

[0138] Figure 7 e shows cardiomyocytes isolated from sham- and TAC-operated mice and stained to visualize DAPI and α-actin. Cells were imaged by confocal microscopy, and representative z-stack images of 3 mice per group are shown. Scale bar 20 μm.

[0139] Figure 7 f shows that adult cardiomyocytes stained as in (e) were evaluated for their ratio of mononuclear to multinucleated myocytes (at least 130 cells were quantified from n=3 mice per group).

[0140] Figure 7 g shows the HW / BW of sham-operated and TAC-operated mice (n = 5 for sham-operated mice; n = 6 for TAC-operated mice; * p < 0.05; two-tailed unpaired t test).

[0141] Figure 7 h, 7i show representative images of H&E (h) and picrosirius red (i) stained tissue sections of sham-operated and TAC-operated mice. Scale bar, 500 μm.

[0142] Figure 7 j shows the relative expression of Col1a1, Col3a1 and TGFb1 mRNA in left ventricular lysates of sham-operated and TAC-operated mice. Data were normalized to sham-operated animals (set to 1.0) (n = 5 for sham-operated animals; n = 6 for TAC-operated animals; data shown are mean ± SEM; * p < 0.05; two-tailed unpaired t test).

[0143] Figure 8 a shows the expression of Atp5a1 mRNA in Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1 11 weeks after AAV9 injection. + and Mlc2v-cre - Relative expression in mice. Data were normalized to Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1. - mice (set to 1.0) (for Mlc2v-cre - Mice, n = 8; for Mlc2v-cre + mice, n = 9; data shown are mean ± SEM; *** p < 0.001; two-tailed unpaired t test).

[0144] Figure 8b shows Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1 + and Mlc2v-cre - Quantification of ATP levels in ventricular lysates of mice (for Mlc2v-cre - Mice, n = 8; for Mlc2v-cre + mice, n = 9; data shown are mean ± SEM; * p < 0.05; two-tailed unpaired t test).

[0145] Figure 8 c shows the Mlc2v-cre injected with AAV9-fl / fl-shAtp5a1 virus + (n=3) and Mlc2v-cre - (n=3) Sections of the left ventricle of mice were stained with H&E and imaged by light microscopy (3 sections per heart (3-5 fields per section) were examined, and representative fields are shown). Scale bar, 200 μm.

[0146] Figure 8 d shows the Mlc2v-cre cells injected with AAV9-fl / fl-shAtp5a1 virus. + and Mlc2v-cre - Cardiomyocytes were isolated from mice and stained to visualize DAPI and α-actin. Cells were imaged by confocal microscopy, and representative z-stack images of 3 mice per group are shown. Scale bar is 20 μm.

[0147] Figure 8 e shows that adult cardiomyocytes stained as in (d) were evaluated for their ratio of mononuclear to multinucleated myocytes (at least 150 cells were quantified from n=3 mice per group).

[0148] Figure 8 f shows the expression of Nppa and Nppb mRNA in Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1 11 weeks after AAV9 injection. + and Mlc2v-cre - Relative expression in mice. Data were normalized to Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1. - mice (set to 1.0) (for Mlc2v-cre - Mice, n = 8; for Mlc2v-cre + mice, n = 9; data shown are mean ± SEM; * p < 0.05; two-tailed unpaired t test).

[0149] Figure 8 g shows Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1 11 weeks after AAV9 injection. + and Mlc2v-cre - LVID in mice;s (for Mlc2v-cre - Mice, n = 8; for Mlc2v-cre + mice, n = 9; data shown are mean ± SEM; *** p < 0.01; two-tailed unpaired t test).

[0150] Figure 8 h shows Mlc2v-cre transduced with AAV9-fl / fl-shAtp5a1 virus + and Mlc2v-cre - Representative images of picrosirius red-stained tissue sections from mice. Scale bar, 500 μm.

[0151] Figure 8 i shows the expression of Col1a1, Col3a1 and TGFb1 mRNA in Mlc2v-cre cells transduced with AAV9-fl / fl-shAtp5a1 virus. + and Mlc2v-cre - Relative expression in left ventricular lysates of mice. Data were normalized to Mlc2v-cre - mice (set to 1.0) (for Mlc2v-cre - Mice, n = 8; for Mlc2v-cre + mice, n = 9; data shown are mean ± SEM; * p < 0.05; two-tailed unpaired t test).

[0152] Figure 8 j shows the relative expression of ATP5A1 mRNA in iPSC-derived human cardiomyocytes (iPSC-hCMs) transduced with lentivirus expressing non-silencing shRNA (nsRNA) or shRNA against ATP5A1 (shATP5A1). Data were normalized to the control NRC expressing nsRNA (set to 1.0) (n = 3 biological replicates per group; data shown are mean ± SD; *** p < 0.001; two-tailed unpaired t test).

[0153] Figure 8k shows the ADP / ATP ratio in iPSC-hCMs transduced with lentivirus expressing nsRNA or shATP5A1 (n = 3 biological replicates per group; data shown are mean ± SD; ** p < 0.01; two-tailed unpaired t test).

[0154] Figure 8 l, 8m show the quantitative results of ADP (l) and ATP (m) levels in iPSC-hCMs transduced with lentivirus expressing nsRNA or shATP5A1 (for both groups, n = 3; data shown are mean ± SD; ** p < 0.01; two-tailed unpaired t test).

[0155] Figure 8 n shows iPSC-hCMs transduced with lentivirus expressing nsRNA or shATP5A1 were stained to visualize DAPI and phalloidin and imaged by confocal microscopy. Representative fields of 3 biological replicates are shown in the figure. Scale bar is 20 μm.

[0156] Figure 8 o shows the quantitative results of the percentage of multinucleated cells in iPSC-hCMs treated as in (n) (n=3 biological replicates, approximately 100 cells analyzed in each experiment and condition; data shown are mean±SD; * p < 0.05; two-tailed unpaired t test).

[0157] Figure 8 p shows the evaluation of cell size of iPSC-hCMs treated as in (n) using ImageJ (n = 3 independent experiments, approximately 100 cells analyzed in each experiment and condition; data shown are mean ± SD; * p < 0.05; two-tailed unpaired t test).

[0158] Figure 8 q shows the relative expression of Atp5a1 mRNA in NRCs transduced with lentivirus expressing nsRNA or shAtp5a1. Data were normalized to control NRCs expressing nsRNA (set to 1.0) (n = 3 biological replicates per group; data shown are mean ± SD; *** p < 0.001; two-tailed unpaired t test).

[0159] Figure 8 r shows Atp5a1 protein levels in NRCs transduced with nsRNA or shAtp5a1 assessed by immunoblotting. Loading was normalized to cardiac actin. Figure 8s shows the ADP / ATP ratio in NRCs transduced with lentivirus expressing nsRNA or Atp5a1 shRNA as indicated ( n = 3 biological replicates per group; data shown are mean ± SD; ** p < 0.01; two-tailed unpaired t test).

[0160] Figure 8 t, 8u show the quantitative results of ADP (t) and ATP (u) levels in NRCs transduced with lentivirus expressing nsRNA or Atp5a1 shRNA (for both groups, n = 3; data shown are mean ± SD; ** p < 0.01; two-tailed unpaired t test).

[0161] Figure 8 v shows NRCs transduced with lentivirus expressing nsRNA or Atp5a1 shRNA were stained to visualize phalloidin and DAPI and imaged by confocal microscopy. Representative fields of n=3 biological replicates are shown in the figure. Scale bar is 20 μm.

[0162] Figure 8 w shows the quantitative results of the percentage of multinucleated cells in NRCs treated as in (v) (n=3 biological replicates, approximately 100 cells were analyzed in each experiment and condition; data shown are mean±SD; * p < 0.05; two-tailed unpaired t test).

[0163] Figure 8 x shows the cell size of NRCs treated as in (v) assessed using ImageJ (n=3 independent experiments, approximately 100 cells analyzed in each experiment and condition; data shown are mean ± SD; * p < 0.05; two-tailed unpaired t test).

[0164] Figure 8 y shows the incorporation of [ 3 H] Leucine was evaluated. Data are expressed as incorporated radioactivity relative to the control NRC expressing nsRNA (set to 1.0) (n = 4 biological replicates per group; data shown are mean ± SEM; * p < 0.05; two-tailed unpaired t test).

[0165] Fig. 9a, 9b show the relative expression of Atp5a1 mRNA in the ventricles of control (Hif1αfl / fl) mice and Hif1αcKO mice (a) or control (Vhl fl / fl) mice and Vhl cKO mice (b) after sham or TAC surgery. Data were normalized to control mice (set to 1.0) (for (a) and (b), n = 5 mice per group; data shown are mean ± SEM; * , %p<0.05; ** p<0.01; one-way ANOVA with Bonferroni correction for (a) and two-tailed unpaired t-test for (b).

[0166] Fig. 9 c shows ventricular lysates from sham- or TAC-operated control (Hif1αfl / fl) and Hif1αcKO mice (left panel) or control (Vhl fl / fl) and Vhl cKO mice (right panel) were processed for immunoblotting with antibodies against Hif1α and Atp5a1. Loading was normalized to cardiac actin.

[0167] Fig. 9 d, 9e show the quantitative results of ATP content (d) and ejection fraction (e) in left ventricular biopsies of control (Hif1αfl / fl) mice and ventricle-specific Hif1α conditional knockout (Hif1αcKO) mice (d) that underwent sham or TAC surgery (for (d) and (e), n = 5 mice per group; data shown are mean ± SEM; * , % p < 0.05; one-way ANOVA and Bonferroni correction).

[0168] Fig. 9 f, 9g show the quantitative results of ATP content (f) and ejection fraction (g) in left ventricular biopsy tissues of ventricle-specific Vhl conditional knockout (Vhl cKO) mice and corresponding control (Vhlfl / fl) mice (g) (for (f) and (g), n = 5 mice in each group; data shown are mean ± SEM; * p<0.05; ** p < 0.01; two-tailed unpaired t test).

[0169] Fig. 9h shows the expression of miRNAs containing putative HREs in their promoters from ventricular lysates of TAC-operated Hif1α cKO mice versus TAC-operated control animals or Vhl cKO mice versus control animals (p<0.0001 between technical quadruplicate assays; p<0.05 in biological triplicate assays with mean signal intensity 1-fold background).

[0170] Fig. 9 i shows the relative expression of mir27b, ​​Vegfa and Ldha mRNA in the ventricles of control (Hif1αfl / fl) mice and Hif1αcKO mice that underwent sham or TAC surgery. Data were normalized to sham-operated control mice (set to 1.0) (n=5 mice per group; data shown are mean ± SEM; * , % p < 0.05; one-way ANOVA and Bonferroni correction).

[0171] Fig. 9 j shows the relative expression of mir27b RNA in the ventricles of control (Vhl fl / fl) mice and Vhl cKO mice. Data were normalized to control mice (set to 1.0) (n=5 mice per group; data shown are mean ± SEM; *** p < 0.001; two-tailed unpaired t test).

[0172] Fig. 9 k-9m shows the relative expression levels of AmpO (k), mature miR27b-3p, miR23b-3p and miR24-3p (l) and miR27b-5p, miR23b-5p and miR24-5p (m) in ventricular lysates of wild-type C57BL / 6J mice subjected to sham or TAC surgery. Data were normalized to sham-operated control mice (set to 1.0) (n=5 for sham surgery; n=8 for TAC surgery; data shown are mean ± SEM; * p<0.05; ** p<0.01; *** p < 0.001; two-tailed unpaired t test).

[0173] Fig. 9n-9p shows the relative expression of AmpO (n), mature miR27b-3p, miR23b-3p and miR24-3p (o), and miR27b-5p, miR23b-5p and miR24-5p (p) in NRCs ectopically expressing a blank control vector or HIF1α△ODD. The data were normalized to NRCs transduced with a blank control vector (set to 1.0) (n = 5 biological replicates per group; data shown are mean ± SEM; ** p < 0.01; two-tailed unpaired t test).

[0174] Fig. 9 q shows the incorporation of [ 3 H]leucine was assessed. Data are expressed as incorporated radioactivity relative to the NRC of mock treatment (set as 1.0) (n = 4 biological replicates per group; data shown are mean ± SEM; *** p < 0.001; two-tailed unpaired t test).

[0175] Fig. 9 r-9t shows the relative expression of AmpO (r), mature miR27b-3p, miR23b-3p and miR24-3p (s), and miR27b-5p, miR23b-5p and miR24-5p (t) in NRCs treated with PBS (mock) or T3. Data were normalized to mock-treated NRCs (set to 1.0) (n = 5 biological replicates per group; data shown are mean ± SEM; *** p < 0.001; two-tailed unpaired t test).

[0176] Fig. 9 u shows the relative expression of Hif1α, mir27b, ​​Glut1, and Vegfa mRNA in NRCs stimulated with T3 and transduced with non-silencing control shRNA (nsRNA) or shRNA against Hif1α (shHif1α). Data were normalized to control NRCs infected with nsRNA (set to 1.0) (n = 3 biological replicates per group; data shown are mean ± SD; * , % p < 0.05; one-way ANOVA and Bonferroni correction).

[0177] Fig. 9 v shows the sequence of mir27b promoter of human, monkey, opossum, rat and mouse, which contains the conserved HRE located 162 bp upstream of the transcription start site of precursor mir27b. HRE is shown in red, and the core HRE motif is capitalized.

[0178] Fig. 9 w shows the co-transfection of wild-type (wt) or HRE mutant (mut) mir27b promoter fused with luciferase with different doses of blank control vector or HIF1α△ODD. The data were normalized to the wild-type promoter transfected with blank control vector (set as 1.0) (n = 4 biological replicates per group; data shown are mean ± SEM; * p < 0.05; one-way ANOVA followed by Dunnett's post-test).

[0179] Fig. 9 x shows co-transfection of mir23b and mir24-1 promoters fused with luciferase with different doses of blank vector control or HIF1α△ODD. Data were normalized to the luciferase vector transfected with the blank control vector (set as 1.0) (n = 4 biological replicates per group; data shown are mean ± SEM; * p < 0.05; one-way ANOVA followed by Dunnett's post-test).

[0180] Fig. 9 y shows that NRCs were transduced with lentivirus expressing nsRNA or anti-Vhl shRNA (shVhl) and processed for chromatin immunoprecipitation with HIF1α-specific antibody (IP:HIF1α) or control isotype-matched antibody (IgG control). Binding of the Hif1α promoter was analyzed by qPCR. Data shown are relative to chromatin immunoprecipitation of nuclear lysates of NRCs expressing nsRNA using 1g control antibody (set to 1.0) (n=3 biological replicates per group; data shown are mean±SD; *** p < 0.001; two-tailed unpaired t test).

[0181] Fig. 9 z shows that Hif1α and Vhl protein levels in NRCs transduced with nsRNA or shVhl were assessed by immunoblotting. Loading was normalized to cardiac actin.

[0182] Fig.10 a shows the target gene recognition motifs in the 3'UTR of Atp5a1 of human and mouse. The miR27b-5p seed sequence and the corresponding target region on Atp5a1 are indicated by alignment.

[0183] Fig.10b shows co-transfection of wild-type (wt) or mir27b binding site mutant (mut) Atp5a1 3'UTR fused to luciferase with different doses of control, mir27b-3p or mir27b-5p mimics. Data were normalized to the wild-type promoter transfected with control mimics (set as 1.0) (n = 4 biological replicates per group; data shown are mean ± SEM; ** p<0.01; *** p<0.001; one-way ANOVA followed by Dunnett's post-test).

[0184] Fig.10 c shows Atp5a1 protein levels in NRCs transduced with a control vector or ectopic mir27b assessed by immunoblotting. Loadings were normalized to cardiac actin.

[0185] Fig.10 d, 10e show the relative expression of mir27b precursor (d) and mature mir27b-3p and mir27b-5p (e) in NRCs ectopically expressing a blank control vector or mir27b. The data were normalized to NRCs transduced with a blank control vector (set as 1.0) (n = 3 biological replicates per group; data shown are mean ± SD; * p<0.05; *** p < 0.001; two-tailed unpaired t test).

[0186] Fig.10 f shows the relative expression level of Atp5a1 mRNA in NRCs transfected with different concentrations of control, miR27b-3p and miR27b-5p mimics. The data were normalized to the control mimic (set as 1.0) (n = 3 replicates per group; data shown are mean ± SD; * p<0.05; *** p<0.001; one-way ANOVA followed by Dunnett's post-test).

[0187] Fig.10 g, 10h show the relative expression of mature miR27b-5p (g) and miR27b-3p (h) in NRCs transduced with blank vector control or HIF1α△ODD and treated with scrLNA or miR27b-5p LNA. Data were normalized to NRCs transduced with blank control vector (set to 1.0) (n = 5 biological replicates per group; data shown are mean ± SEM; * , % p < 0.05; one-way ANOVA and Bonferroni correction).

[0188] Fig.10 i shows immunoblots of Hif1α and Atp5a1 expression in NRCs transduced with lentivirus expressing a control vector or HIF1αΔODD and treated with scrambled control LNA (scrLNA) or miR27b-5p LNA. Loading was normalized to cardiac actin.

[0189] Fig.10 j, 10k show the relative expression of mature miR27b-5p (j) and miR27b-3p (k) in NRC treated with PBS (mock) or T3 in the presence of scrRNA or miR27b-5p LNA. Data were normalized to mock-treated cells (set to 1.0) (n = 5 biological replicates per group; data shown are mean ± SEM; * , % p < 0.05; one-way ANOVA and Bonferroni correction).

[0190] Fig.10 l shows the evaluation of Hif1α, miR27b, and Atp5a1 RNA levels in NRCs treated with PBS (mock) or T3 in the presence of scrRNA or miR27b-5p LNA. Data were normalized to NRCs treated with scrLNA (set to 1.0) (n = 4 biological replicates per group; data shown are mean ± SEM; * , % p < 0.05; one-way ANOVA and Bonferroni correction).

[0191] Fig.10 m shows the assessment of Atp5a1 protein levels in NRCs treated as in (l) by immunoblotting. Loading was normalized to cardiac actin.

[0192] Fig.10 n, 10o show the enzyme activity of ATP synthase in NRCs transduced and treated as indicated. Data were normalized to the control group (set to 1.0) (n = 5 biological replicates per group; data shown are mean ± SEM; * , %p<0.05; ** p<0.01; *** p < 0.001; two-tailed unpaired t-test (n) or one-way ANOVA followed by Bonferroni correction (o).

[0193] Fig.10 p shows Atp5a1 protein levels in NRCs transduced with a control vector or ectopic ATP5A1 assessed by immunoblotting. Loadings were normalized to cardiac actin.

[0194] Fig.11 a shows the expression of Nppa and Nppb mRNA in Mlc2v-cre transduced with AAV9-fl / fl-mir27b 11 weeks after AAV9 injection. + and Mlc2v-cre - Relative expression in mice. Data were normalized to Mlc2v-cre transduced with AAV9-fl / fl-mir27b. - mice (set to 1.0) (for Mlc2v-cre - Mice, n = 6; for Mlc2v-cre + mice, n = 8; data shown are mean ± SEM; * p < 0.05; two-tailed unpaired t test).

[0195] Fig.11 b shows Mlc2v-cre transduced with AAV9-fl / fl-mir27b 11 weeks after AAV9 injection + and Mlc2v-cre - LVID in mice;s (for Mlc2v-cre - Mice, n = 6; for Mlc2v-cre + mice, n = 8; data shown are mean ± SEM; * p < 0.05; two-tailed unpaired t test).

[0196] Fig.11 c shows the expression of Atp5a1 mRNA in Mlc2v-cre transduced with AAV9-fl / fl-mir27b 11 weeks after AAV9 injection by qPCR. + and Mlc2v-cre - Relative expression in mice. Data were normalized to Mlc2v-cre transduced with AAV9-fl / fl-mir27b. - mice (set to 1.0) (for Mlc2v-cre - Mice, n = 6; for Mlc2v-cre + mice, n = 8; data shown are mean ± SEM; *** p < 0.001; two-tailed unpaired t test).

[0197] Fig.11 d shows the Mlc2v-cre transduced with AAV9-fl / fl-mir27b + and Mlc2v-cre -Left ventricular sections obtained from mice 11 weeks after AAV9 injection were stained with H&E and imaged by light microscopy (3 sections per heart (3-5 fields per section) were examined and representative fields are shown; a total of 3 hearts were analyzed per group). Scale bar, 200 μm.

[0198] Fig.11 e shows the Mlc2v-cre from the cells injected with AAV9-fl / fl-mir27b virus + and Mlc2v-cre - Cardiomyocytes were isolated from mice and stained to visualize DAPI and α-actin. Cells were imaged by confocal microscopy, and representative z-stack images of 3 mice per group are shown. Scale bar is 20 μm.

[0199] Fig.11 f shows that adult cardiomyocytes stained as in (e) were evaluated for their ratio of mononuclear to multinucleated myocytes (at least 160 cells were analyzed from n=3 mice per group).

[0200] Fig.11 g shows Mlc2v-cre transduced with AAV9-fl / fl-mir27b virus + and Mlc2v-cre - Representative images of picrosirius red-stained tissue sections from mice. Scale bar, 500 μm.

[0201] Fig.11 h shows the expression of Col1a1, Col3a1 and TGFb1 mRNA in Mlc2v-cre injected with AAV9-fl / fl-mir27b virus. + and Mlc2v-cre - Relative expression in left ventricular lysates of mice. Data were normalized to Mlc2v-cre - mice (set to 1.0) (for Mlc2v-cre - Mice, n = 6; for Mlc2v-cre + mice, n = 8; results shown are mean ± SEM; * p < 0.05; two-tailed unpaired t test).

[0202] Fig.11i shows the results of longitudinal monitoring of aortic velocity in C57BL / 6J mice that underwent sham or TAC surgery and were treated with scrambled LNA (scrLNA) or miR27b-5p LNA. Arrows in the figure indicate LNA injection (for sham scrLNA, n=5; for sham miR27b-5p LNA, n=5; for TAC scrLNA, n=7; for TAC miR27b-5p LNA, n=8; data shown are mean ± SEM).

[0203] Fig.11 j shows left ventricular sections of C57BL / 6J mice that underwent sham or TAC surgery and were treated with scrLNA or miR27b-5p LNA were stained with H&E and imaged by light microscopy (3 sections per heart (2-4 fields per section) were examined and representative fields are shown; a total of 3 hearts were analyzed per group). Scale bar, 200 μm.

[0204] Fig.11 k shows cardiomyocytes isolated from C57BL / 6J mice that were sham-operated or TAC-operated and treated with scrLNA or miR27b-5p LNA and stained to visualize DAPI and α-actin. Cells were imaged by confocal microscopy, and representative z-stack images of 3 mice per group are shown. Scale bar is 20 μm.

[0205] Fig.11 l shows that the ratio of mononuclear to multinucleated myocytes was assessed for adult cardiomyocytes stained as in (d) (at least 150 cells were analyzed from n=3 mice per group).

[0206] Fig.11 m shows representative images of picrosirius red-stained tissue sections from C57BL / 6J mice that underwent sham or TAC surgery and were treated with scrLNA or miR27b-5p LNA. Scale bar, 500 μm.

[0207] Fig.11 n shows the relative expression of Col1a1, Col3a1 and TGFb1 mRNA in left ventricular lysates of C57BL / 6J mice treated with scrLNA or miR27b-5p LNA and subjected to sham or TAC surgery by qPCR. Data were normalized to mice treated with scrLNA and subjected to sham surgery (set to 1.0) (n=5 for sham scrLNA; n=5 for sham miR27b-5p LNA; n=7 for TAC scrLNA; n=8 for TAC miR27b-5p LNA; data shown are mean ± SEM; *, % p < 0.05; one-way ANOVA and Bonferroni correction).

[0208] Fig.12 a shows the relative expression of Mthfd1l mRNA in NRCs expressing a blank control vector or ectopic MTHFD1L. Data were normalized to NRCs expressing a blank control vector (set to 1.0) (n = 3 biological replicates per group; results shown are mean ± SD; *** p < 0.05; two-tailed unpaired t test).

[0209] Fig.12 b shows immunoblots of NRCs transduced with lentivirus expressing a control vector or MTHFD1L using an antibody against Mthfd1l. Loading was normalized to cardiac actin.

[0210] Fig.12 c-12h shows the quantification of ATP (c, e, g) and ADP (d, e, h) levels in NRCs transduced and treated as indicated (n = 4 biological replicates per group; results shown are mean ± SD; * , % p < 0.05; one-way ANOVA followed by Bonferroni correction).

[0211] Fig.13 a shows the incorporation of [ 3 Evaluation of H]leucine. Data are expressed as incorporated radioactivity relative to control (mock) NRC treated with scrLNA (set to 1.0) (n = 4 biological replicates per group; results shown are mean ± SEM; * , % p < 0.05; one-way ANOVA followed by Bonferroni correction).

[0212] Fig.13 b shows the relative amount of formate in NRCs stimulated with T3 and treated with scrLNA or miR27b-5p LNA (n = 5 biological replicates per group; results shown are mean ± SEM; * , % p < 0.05; one-way ANOVA followed by Bonferroni correction).

[0213] Fig.13 c shows the relative ADP / ATP ratio in NRCs stimulated with T3 and treated with scrLNA or miR27b-5p LNA (n = 5 biological replicates per group; results shown are mean ± SEM; *, % p < 0.05; one-way ANOVA followed by Bonferroni correction).

[0214] Fig.13 d shows a heat map of relative metabolite abundance in NRCs stimulated with T3 and treated with scrLNA or miR27b-5p LNA. The metabolites depicted met "log2 (fold change) > 0.4" in at least one treatment group (n = 4 biological replicates per group) compared to the corresponding control group and met "p value < 0.01" after adjustment. Fig.13 e shows the incorporation of nucleic acids into NRCs stimulated with T3 and treated with scrLNA or miR27b-5p LNA. 14 C] glucose, 14 C]serine and [ 14 C] glycine derived [ 14 C] relative amount of carbon (n = 5 biological replicates per group; results shown are mean ± SEM; * p < 0.05; one-way ANOVA followed by Bonferroni correction).

[0215] Fig.14 a shows the results of differential analysis of left ventricular metabolites in C57BL / 6J mice injected with scrLNA or mir27b-5p L and subjected to sham or TAC surgery; circles reflect -log 10 (Adjusted p-value); color of circles reflects log2-fold change compared to indicated control group (n=6 biological replicates per group).

[0216] Fig.14 b shows the results of hierarchical clustering analysis of metabolites in the indicated samples measured in duplicate (n = 6 biological replicates per group).

[0217] Fig.15 a shows the principal component analysis (PCA) results of the indicated cohort.

[0218] Fig.15 b, 15c show the results of principal component analysis of left ventricle samples from sham-operated or TAC-operated mice with active (scrambled, b) or LNA-mediated inhibition of miR27b-5p (c), respectively. The lipid species indicated by the arrows explained 15% of the variance covered by PC1 (nonparametric Wilcoxon signed-rank test; n = 5 per group).

[0219] Fig.15d shows a bar graph of the distribution of saturation in the four cohorts shown (mean + / - standard deviation). Lipids were grouped according to the number of double bonds (db), with all species with more than 6 db clustered in a single group (6+). The lipids analyzed included the following 19 lipid classes: cholesterol esters (CE), ceramides (Cer), cholesterol (Choi), cardiolipin (CL), diacylglycerols (DAG), lysophospholipids (LPA), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), ether-linked LPE (LPE-O - ), lysophosphatidylinositol (LPI), phosphatidylcholine (PC), ether-linked PC (PC-O - ), phosphatidylethanolamine (PE), ether-linked PE (PE-O - ), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), sphingomyelin (SM), and triglycerides (adjusted p value < 0.001 *** , adjusted p value < 0.01 ** , adjusted p value < 0.1 * ; Nonparametric Wilcoxon signed-rank test; n = 5 biological samples per group).

[0220] Fig.15 e shows a bar graph of the total length distribution in the four indicated cohorts (mean + / - SD). Lipids (analyzed as in d) were grouped according to the total length of their acyl chains (i.e., number of carbon atoms). Significant comparisons are indicated with asterisks (adjusted p value < 0.001 *** , adjusted p value < 0.01 ** , adjusted p value < 0.1 * ; Nonparametric Wilcoxon signed-rank test; n = 5 biological samples per group).

[0221] Fig.15 f shows the results obtained by subtracting the average molar percent abundance of lipid species in sham-operated control mice from the average molar percent abundance of lipid species in left ventricular biopsies of mice treated with scrLNA and subjected to TAC surgery.

[0222] Fig.15 g shows the results obtained by subtracting the average molar abundance of lipid species in sham-operated control mice with inhibited (LNA) miR27b-5p from the average molar abundance of lipid species in mice injected with miR27b-5p LNA and subjected to TAC surgery.

[0223] Fig.15h shows the relative expression of the indicated mRNA in C57BL / 6J mice treated with scrLNA or miR27b-5p LNA and subjected to sham or TAC surgery by qPCR. Data were normalized to mice treated with scrLNA and subjected to sham surgery (set to 1.0) (n=5 for sham scrLNA; n=5 for sham miR27b-5p LNA; n=7 for TAC scrLNA; n=8 for TAC miR27b-5p LNA; data shown are mean ± SEM; * , % p < 0.05; one-way ANOVA and Bonferroni correction).

[0224] Fig.15 i shows that [1- 14 C]-palmitate 14 Oxidation of CO2. All values ​​were normalized to protein content (n = 5 for sham scrLNA; n = 5 for sham miR27b-5p LNA; n = 6 for TAC scrLNA; n = 6 for TAC miR27b-5p LNA; data shown are mean ± SD; * , % p < 0.05; one-way ANOVA and Bonferroni correction).

[0225] Fig.16 a, 16b show the quantitative results of ADP (a) and ATP (b) levels in NRCs treated with PBS or 10 μM ADP for 3 days (n = 4 biological replicates per group; results shown are mean ± SD; * , % p < 0.05; one-way ANOVA followed by Bonferroni correction).

[0226] Fig.16 c, 16d show the quantitative results of ADP (c) and ATP (d) levels in NRCs treated with PBS or 20 nM oligomycin (n = 3 biological replicates per group; results shown are mean ± SD; * , % p < 0.05; one-way ANOVA followed by Bonferroni correction).

[0227] Fig.16 e shows NRC treated with PBS or 10 μM ADP for 3 days were stained to visualize DAPI and α-actin and imaged by confocal microscopy. Representative fields from three independent experiments are shown in the figure. Scale bar is 5 μm.

[0228] Fig.16 f shows NRC treated with PBS or oligomycin were stained to visualize DAPI and α-actin and imaged by confocal microscopy. An average of 4 fields were imaged for each condition and experiment, and representative fields from three independent experiments are shown. Scale bar 50 μm.

[0229] Fig.16 g, 16h shows that NRCs treated and imaged as in (e, f) were evaluated for multinucleation (at least 110 cells were quantified for each sample in n = 3 independent experiments; results shown are mean ± SD; ** p < 0.01; two-tailed unpaired t test).

[0230] Fig.16 i, 16j show the evaluation of the cell surface area of ​​NRCs treated and imaged as in (e, f) using ImageJ (at least 110 cells were quantified for each sample in n = 3 independent experiments; results shown are mean ± SD; * p<0.05; ** p < 0.01; two-tailed unpaired t test).

[0231] Fig.17 a-17d shows NRC transduced with the indicated lentiviruses stained to visualize the cardiac-specific marker α-actin, DAPI, and phosphorylated histone H3 (p-histone H3) for evaluation of cell mitosis and imaged by confocal microscopy. p-histone H3-positive cardiomyocytes were quantified. For each condition, 3 biological replicates were analyzed (3-4 regions were selected for each biological replicate), and representative regions are shown. Scale bar 100 μm.

[0232] Fig.17 e shows the relative expression of Mthfd1l mRNA in NRCs expressing nsRNA or shMthfd1l. Data were normalized to NRCs expressing nsRNA (set to 1.0) (n = 3 biological replicates in each group; results shown are mean ± SD; *** p < 0.05; two-tailed unpaired t test).

[0233] Fig.17 f shows immunoblot of NRCs transduced with lentivirus expressing nsRNA or shMthfd11 using an antibody against Mthfd11. Loading was normalized to cardiac actin.

[0234] Fig.17g, 17h shows NRC transduced with the indicated lentiviruses stained to visualize the cardiac-specific marker α-actin, DAPI, and phosphorylated histone H3 (p-histone H3) for evaluation of cell mitosis and imaged by confocal microscopy. p-histone H3-positive cardiomyocytes were quantified. For each condition, 3 biological replicates were analyzed (3-4 regions were selected for each biological replicate), and representative regions are shown. Scale bar is 100 μm.

[0235] Fig.18 a shows the Mlc2v-cre cells that were sham-operated or TAC-operated and transduced with AAV9-fl / fl-shMthfd1l + and Mlc2v-cre - Sections of the left ventricle obtained from mice 11 weeks after AAV9 injection were stained with H&E and imaged using light microscopy (3 sections per heart (2-4 fields per section) were examined, and representative fields are shown; a total of 3 hearts were analyzed per group). Scale bar, 200 μm.

[0236] Fig.18 b shows Mlc2v-cre after sham or TAC surgery + and Mlc2v-cre - Left ventricular internal systolic diameter (LVID; s) of mice transduced with AAV9-fl / fl-shMthfd1l 11 weeks after AAV9 injection (for sham-operated Mlc2v-cre - Mice, n = 4; for sham-operated Mlc2v-cre + Mice, n = 5; for Mlc2v-cre - Mice, n = 8; for Mlc2v-cre + mice, n = 7; data shown are mean ± SEM; * , % p < 0.05; one-way ANOVA followed by Bonferroni correction).

[0237] Fig.18 c, 18d show Mlc2v-cre after sham surgery or TAC surgery + and Mlc2v-cre - Relative expression of Nppa and Nppb (c) and Mthfd11 mRNA (d) in ventricular lysates from mice transduced with AAV9-fl / fl-shMthfd11 1 week after AAV9 injection. Data were normalized to sham-operated Mlc2v-cre - Mice (set as 1.0) (for sham-operated Mlc2v-cre- Mice, n = 4; for sham-operated Mlc2v-cre + Mice, n = 5; for Mlc2v-cre - Mice, n = 8; for Mlc2v-cre + mice, n = 7; data shown are mean ± SEM; * , % p < 0.05; one-way ANOVA followed by Bonferroni correction).

[0238] Fig.18 e shows the Mlc2v-cre cells from sham-operated or TAC-operated mice transduced with AAV9-fl / fl-shMthfd1l. + and Mlc2v-cre - Cardiomyocytes were isolated from mice and stained to visualize DAPI and α-actin. Cells were imaged by confocal microscopy, and representative z-stack images of 3 mice per group are shown. Scale bar is 20 μm.

[0239] Fig.18 f shows that adult cardiomyocytes stained as in (e) were evaluated for their ratio of mononuclear to multinucleated myocytes (at least 150 cells were analyzed from n=3 mice per group).

[0240] Fig.18 g shows a sham operation or TAC operation and transduction of Mlc2v-cre with AAV9-fl / fl-shMthfd1l + and Mlc2v-cre - Representative images of picrosirius red-stained tissue sections from mice. Scale bar, 500 μm.

[0241] Fig.18 h shows the expression of Col1a1, Col3a1 and TGFb1 mRNA in Mlc2v-cre mice after sham surgery or TAC surgery and injection of AAV9-fl / fl-shMthfd1l virus. + and Mlc2v-cre - Relative expression in left ventricular lysates of C57BL / 6J mice. Data were normalized to sham-operated Mlc2v-cre - Mice (set as 1.0) (for sham-operated Mlc2v-cre - Mice, n = 4; for sham-operated Mlc2v-cre + Mice, n = 5; for Mlc2v-cre - Mice, n = 8; for Mlc2v-cre +mice, n = 7; data shown are mean ± SEM; * , % p < 0.05; one-way ANOVA followed by Bonferroni correction).

[0242] Fig.18 i shows the Mlc2v-cre co-transduced with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l + and Mlc2v-cre - Left ventricular sections obtained from mice 11 weeks after AAV9 injection were stained with H&E and imaged using light microscopy (3 sections per heart (3-5 fields per section) were examined and representative fields are shown; a total of 3 hearts were analyzed per group). Scale bar, 200 μm.

[0243] Fig.18 j shows the results from the co-transduction of AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l viruses. Mlc2v-cre + and Mlc2v-cre - Cardiomyocytes were isolated from mice and stained to visualize DAPI and α-actin. Cells were imaged by confocal microscopy, and representative z-stack images of 3 mice per group are shown. Scale bar, 20 μm.

[0244] Fig.18 k shows that the ratio of mononuclear to multinucleated myocytes was assessed for adult cardiomyocytes stained as in (n) (at least 150 cells were analyzed from n=3 mice per group).

[0245] Fig.18 l shows the cells co-transduced with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l 11 weeks after AAV9 injection. Mlc2v-cre + and Mlc2v-cre - LVID;s in mice (n = 6 mice per group; data shown are means ± SEM).

[0246] Fig.18 m-18o shows the expression of Nppa and Nppb (m), Atp5a1 (n), and Mthfd1l mRNA (o) in Mlc2v-cre cells co-transduced with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l 1 week after AAV9 injection. +and Mlc2v-cre - Relative expression in ventricular lysates of mice. Data were normalized to Mlc2v-cre - mice (set as 1.0) (n = 6 mice per group; data shown are mean ± SEM; *** p < 0.001; two-tailed unpaired t test).

[0247] Fig.18 p shows Mlc2v-cre co-transduced with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l viruses + and Mlc2v-cre - Representative images of picrosirius red-stained tissue sections from mice. Scale bar, 500 μm.

[0248] Fig.18 q shows Col1a1 , Col3a1 and TGFb1 mRNA was expressed in cells co-transduced with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l viruses. Mlc2v-cre + and Mlc2v-cre - Relative expression in left ventricular lysates of mice. Data were normalized to Mlc2v-cre - mice (set to 1.0) (n = 6 mice per group; data shown are means ± SEM; * p < 0.05; two-tailed unpaired t test).

[0249] Fig.19 a, 19b show the relative expression of Ccnd1 (a) and Ccne1 (b) mRNA in NRCs treated as indicated. Data were normalized to control infected cells transfected with non-silencing siRNA (set to 1.0) (n = 3 biological replicates per group; data shown are mean ± SD; * p<0.05; ** p < 0.01; one-way ANOVA with Bonferroni correction).

[0250] Fig.19 c shows NRCs transduced with lentivirus expressing empty vector control or HIF1aΔODD and transfected as indicated were stained to visualize DAPI, Ki67, and α-actin and imaged by confocal microscopy. An average of 4 fields were imaged for each condition and experiment, and representative fields from three independent experiments are shown. Scale bar, 50 μm.

[0251] Fig.19 d, 19e show the quantitative results of the percentage of multinucleated cells (d) and Ki67-positive cells (e) in NRCs treated as in (c) (n = 3 independent experiments, at least 100 cells were analyzed in each experiment and condition; data shown are mean ± SD; * , % p < 0.05; one-way ANOVA and Bonferroni correction).

[0252] Fig.19 f shows the evaluation of the cell size of NRCs treated as in (c) using ImageJ (n = 3 independent experiments, at least 100 cells were analyzed in each experiment and condition; data shown are mean ± SD; * , % p < 0.05; one-way ANOVA and Bonferroni correction).

[0253] Fig.19 g shows the relative expression of Cdkn1b mRNA in NRCs treated as indicated. Data were normalized to cells transfected with non-silencing siRNA (set to 1.0) (n = 3 biological replicates per group; data shown are mean ± SD; ** p < 0.01; two-tailed unpaired t test).

[0254] Fig.19 h shows NRCs transfected with non-silencing siRNA or Cdkn1b siRNA were stained to visualize DAPI, Ki67, and α-actin and imaged by confocal microscopy. An average of 4 fields were imaged for each condition and experiment, and representative fields from three independent experiments are shown. Scale bar, 50 μm.

[0255] Fig.19 i, 19j show the quantitative results of the percentage of multinucleated cells (i) and Ki67-positive cells (j) in NRCs treated as in (h) (n = 3 independent experiments, at least 100 cells were analyzed in each experiment and condition; data shown are mean ± SD; * p < 0.05; two-tailed unpaired t test).

[0256] Fig.19 k shows the evaluation of the cell size of NRCs treated as in (h) using ImageJ (n = 3 independent experiments, at least 100 cells were analyzed in each experiment and condition; data shown are mean ± SD; * p < 0.05; two-tailed unpaired t test).

[0257] Fig. 20a shows the relative expression of Aldh1l1 mRNA in left ventricular biopsies of C57BL / 6J mice subjected to sham or TAC surgery by qPCR. Data are presented as 2^-dCt relative to Hprt1 (n=5 for sham surgery; n=7 for TAC surgery; data shown are mean ± SEM; ** p < 0.01; two-tailed unpaired t test).

[0258] Fig. 20 b shows the relative expression of ALDH1L1 mRNA in left ventricular biopsies of patients with hypertrophic cardiomyopathy (HCM) and aortic stenosis (AS) relative to healthy controls. Data are shown as 2^-dCt relative to HPRT1 (for healthy controls, n=4; for AS patients, n=10; for HCM patients, n=11; data shown are mean ± SEM).

[0259] Fig. 20 c shows the quantification of NADPH in NRCs treated as indicated. All values ​​were normalized to protein content (n=3 biological replicates per group; data shown are mean±SD).

[0260] Fig. 20 d shows immunoblots using methylated lysine antibodies from left ventricular lysates of patients with HCM and aortic stenosis and healthy controls. Loadings were normalized to cardiac actin.

[0261] Fig. 20 e-20j shows immunoblots obtained with methylated lysine antibody from left ventricle lysates of mice treated as indicated. Loadings were normalized to cardiac actin.

[0262] Table 1. Mlc2v-cre injected with AAV9-fl / fl-shAtp5a1 virus + and Mlc2v-cre - Echocardiographic analysis in mice

[0263]

[0264] IVS indicates interventricular septum thickness at diastole (d) and systole (s); LVID indicates left ventricular internal diameter at diastole (d) and systole (s); LVPW indicates left ventricular posterior wall thickness at diastole (d) and systole (s); FS indicates fractional shortening; EF indicates ejection fraction; LVW / BW indicates left ventricular weight / body weight; HW / BW indicates heart weight / body weight. The values ​​shown are mean ± sem; * P < 0.05; **P < 0.01; two-tailed unpaired t test.

[0265] Table 2. Mlc2v-cre injected with AAV9-fl / fl-mir27b virus + and Mlc2v-cre - Echocardiographic analysis in mice

[0266]

[0267] IVS indicates interventricular septum thickness at diastole (d) and systole (s); LVID indicates left ventricular internal diameter at diastole (d) and systole (s); LVPW indicates left ventricular posterior wall thickness at diastole (d) and systole (s); FS indicates fractional shortening; EF indicates ejection fraction; LVW / BW indicates left ventricular weight / body weight; HW / BW indicates heart weight / body weight. The values ​​shown are mean ± sem; * P < 0.05; ** P < 0.01; two-tailed unpaired t test.

[0268] Table 3. Echocardiographic analysis of mice sham- or TAC-operated and injected with scrLNA or miR27b-5p LNA

[0269]

[0270] LVID represents left ventricular internal diameter at diastole (d) and systole (s); LVPW represents left ventricular posterior wall thickness at diastole (d) and systole (s); FS represents fractional shortening; EF represents ejection fraction; LVW / BW represents left ventricular weight / body weight; HW / BW represents heart weight / body weight. The values ​​shown are mean ± sem; * P < 0.05; ** P<0.01; TAC scrLNA versus sham scrLNA; sham miR27b-5p LNA versus TAC miR27b-5p LNA; two-tailed unpaired t-test.

[0271] Table 4. Mlc2v-cre cells were injected with AAV9-fl / fl-shMthfd1l virus after sham surgery or TAC surgery. + and Mlc2v-cre - Echocardiographic analysis in mice

[0272]

[0273] IVS indicates interventricular septum thickness at diastole (d) and systole (s); LVID indicates left ventricular internal diameter at diastole (d) and systole (s); LVPW indicates left ventricular posterior wall thickness at diastole (d) and systole (s); EF indicates ejection fraction; LVW / BW indicates left ventricular weight / body weight; HW / BW indicates heart weight / body weight. The values ​​shown are mean ± sem; * P < 0.05; ** P<0.01; TAC Mlc2v-cre - Relative to TAC Mlc2v-cre + ; Two-tailed unpaired t test.

[0274] Table 5. Mlc2v-cre co-injected with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l viruses + and Mlc2v-cre - Echocardiographic analysis in mice

[0275]

[0276] IVS indicates interventricular septum thickness at diastole (d) and systole (s); LVID indicates left ventricular internal diameter at diastole (d) and systole (s); LVPW indicates left ventricular posterior wall thickness at diastole (d) and systole (s); FS indicates fractional shortening; EF indicates ejection fraction; LVW / BW indicates left ventricular weight / body weight; HW / BW indicates heart weight / body weight. The values ​​shown are mean ± sem; * P < 0.05; ** P < 0.01; two-tailed unpaired t test.

[0277] Example

[0278] F1F0 ATP synthase inhibition drives cardiac metabolic endoreplication and pathological growth

[0279] To identify mediators of ATP depletion in pathological cardiac hypertrophy in humans and mice, we profiled mRNA levels of all subunits of the ATP synthase complex in biopsies from human HCM and AS patients and in TAC-operated mice ( Figure 1 a, 1b and Figure 7 a). Of the subunits analyzed, ATP5A1 mRNA and protein were consistently decreased in both human and mouse cardiac hypertrophy and significantly correlated with upregulation of the hypertrophy markers natriuretic peptide A (NPPA) and natriuretic peptide B (NPPB), as well as disease indicators of cardiac morphology and function measured by echocardiography ( Figure 1 a-1d and Figure 7a). These changes in ATP5A1 levels are associated with activation of AMP-activated protein kinase (AMPK) through enhanced phosphorylation at Thr172 in diseased myocardium of humans and mice, thereby leading to phosphorylation and downstream inactivation of its direct target acetyl-CoA carboxylase (ACC) ( Figure 1 c, 1d). Crucially, AMPK, although historically described as an AMP-activated kinase, is in fact more sensitive and is activated primarily by ADP. Consistent with suppressed ATP5A1 expression and AMPK activation, the ADP:ATP ratio is elevated in diseased human and mouse left ventricular biopsies ( Figure 1 e, 1f and Figure 7 b). In addition, an increased fraction of cardiomyocytes showing multinucleation was observed in human left ventricular AS and HCM biopsies ( Figure 1 g, 1h and Figure 7 c). In mice, an increase in the fraction of multinucleated cells was also observed after TAC surgery ( Figure 1 i, 1j and Figure 7 d-7f). The TAC regimen simulates human aortic stenosis by surgically constricting the aorta of mice, which results in increased blood flow into the ventricle and pressure overload stress, which leads to pathological cardiac growth and fibrosis, as manifested by increased picrosirius red staining and increased expression of fibrotic marker genes type I collagen alpha 1 (Col1a1), type I collagen alpha 3 (Col3a1), and transforming growth factor beta 1 (TGF1b), as encountered in human aortic stenosis (Barrick, CJ et al., 2007, Am J Physiol Heart Circ Physiol, 292, 2119-2130) ( Figure 7 g-7j).

[0280] To understand the physiological significance of ATP5A1 depletion, we used a novel adeno-associated virus (AAV) 9-based system for in vivo ventricle-specific transgenesis (Mirtschink, P. et al., 2015, Nature, 522, 444-449). Briefly, the delivery of AAV containing TATA-lox-flanked genes or short hairpin RNA (shRNA) confers Cre recombinase (Cre) dependency, which results in tissue-specific ectopic gene or shRNA expression after delivery to tissue-specific Cre transgenic mice (Sauer, B. et al., 1988, Proc Natl Acad Sci USA, 85, 5166-5170). AAV9 containing shRNA targeting Atp5a1 (AAV9-fl / fl-shAtp5a1) was delivered to Mlc2v-Cre transgenic mice (Chen, J. et al., 1998, Development, 125, 1943-1949) that specifically express Cre recombinase in the ventricular myocardium ( Figure 1 k). Delivery of AAV9-fl / fl-shAtp5a1 resulted in a decrease in Atp5a1 mRNA and protein expression ( Fig.11 and Figure 8 a), while activating Ampk and enhancing the phosphorylation of its downstream target Acc ( Fig.11 ), increasing the ADP:ATP level ( Figure 1 m and Figure 8 b), promoted cardiomyocyte multinucleation and overgrowth, and significantly reduced cardiac contractility and fibrosis ( Figure 1 n-1s, Figure 8 c-8i and Table 1). Next, we confirmed these findings in induced pluripotent stem cell (iPSC)-derived human cardiomyocytes and primary neonatal rat cardiomyocytes (NRCs). Human and rat cardiomyocytes were stained with DAPI to visualize nuclei and phalloidin to label filamentous actin and outline the cell surface. Figure 8 As shown in j-8y, knockdown of ATP5A1 by shRNA in human and rat cardiac cells resulted in an increase in the ADP:ATP ratio ( Figure 8 k-8m, 8s-8u), which can be seen through the increase of ADP and ATP depletion levels ( Figure 8 t, 8u) and multinucleation of cardiomyocytes, as well as cell overgrowth as quantified by 2D cell size analysis and leucine incorporation, a readout of protein synthesis as an indirect measure of growth ( Figure 8 n-8p, 8v-8y) (Fukuzawa, J. et al., 2000). Thus, depletion of ATP5A1 is sufficient to induce endoreplication and multinucleation, thereby driving pathological cardiac growth and impairing cardiac function.

[0281] HIF1α regulates the activity of F1F0 ATP synthase through mir27b-5p

[0282] We detected inverse co-regulation of cardiac Hif1α activation with Atp5a1 mRNA and protein expression in TAC-operated ventricular-specific Hif1α conditional knockout (cKO) mice and mice lacking von Hippel Lindau protein (Vhl) in ventricular myocardium, leading to Hif1α accumulation in the myocardium due to inhibition of HIF1α degradation by its oxygen-dependent subunits. Fig. 9 a-9c). Due to the inverse relationship between HIF1α accumulation and ATP5A1 inhibition, ventricular-specific Hif1α cKO mice were protected from the ATP deficiency and contractile dysfunction observed in control HIF1α fl / fl littermates that underwent TAC surgery ( Fig. 9 d, 9e), while Vhl cKO mice showed low ventricular ATP levels associated with decreased contractile function ( Fig. 9 f, 9g). However, direct HIF1α target genes that could mediate the observed effects on Atp5a1 mRNA and ATP levels have repeatedly failed to be pinpointed in both in silico and expression studies (data not shown). This led us to explore the role of Hif1α-regulated miRNAs in mediating these effects. We performed expression profiling of miRNAs in the left ventricle of control mice and TAC-operated ventricle-specific Hif1α cKO mice and ventricle-specific Vhl cKO mice. By comparing expression data within each group and screening for miRNAs containing hypoxia response element (HRE) motifs that are conserved across species, we identified several potential Hif1α-regulated miRNAs ( Fig. 9 h). A subset of these miRNAs have been previously implicated in hypoxia and / or Hif1α dependency. Among these miRNAs, mir27b is unique in that its suppression in TAC-operated Hif1α cKO mice (compared to littermate control Hif1α fl / fl TAC mice) is consistent with the expression pattern of established Hif1α target genes and its upregulation in ventricle-specific Vhl cKO mice ( Fig. 9 i, 9j), indicating a potential regulatory role for Hif1α.

[0283] mir27b is contained in the mir23b-27b-24 cluster in intron 15 of the aminopeptidase O (AmpO) gene of humans and mice (Zhou, Q. et al., 2011, Proc Natl Acad Sci USA, 108, 8287-8292). To determine the dependence of mir27b transcription on stress and Hif1α, we examined the expression of AmpO and all miRNAs contained in the cluster in mice operated on by TAC and in vitro in response to the expression of a constitutively active Hif1α mutant lacking the oxygen-dependent degradation domain (ODD) (termed HIF1α△ODD) or by stimulation with the hypertrophy-inducing β-adrenergic receptor agonist triiodothyronine (T3) ( Fig. 9 TAC surgery in mice resulted in a mild induction of AmpO, essentially unchanged expression of mature miR23b-3p / 5p and miR24-3p / 5p, and an approximately 2.5-fold induction of miR27b-3p / 5p ( Fig. 9 k-9m).

[0284] Ectopic HIF1α△ODD expression in vitro resulted in downregulation of AmpO and unchanged levels of miR23b-3p / 5p and miR24-3p / 5p ( Fig. 9 n-9p), while T3 stimulation induced AmpO expression but not miR23b-3p / 5p or miR24-3p / 5p expression ( Fig. 9 In contrast, mature miR27b-3p / 5p was consistently upregulated in both in vitro models ( Fig. 9 p, 9t). These results suggest that miR27b-3p / 5p is regulated independently of its host gene AmpO and its neighboring miRNAs in response to stress and Hif1α. To confirm that MIR27B is a direct HIF1α target, we stimulated control non-silenced (ns) and shHif1α-transduced NRCs with T3 and analyzed the expression of MIR27B and established HIF1α target genes as controls ( Fig. 9 u). Computer analysis of the cross-species conserved HRE in the mir27b promoter (corresponding to -1 kb upstream of the mir27b transcription start site (TSS)) revealed a conserved HRE motif close to the TSS in humans and mice ( Fig. 9 v). To evaluate the functionality of this HRE, we performed a mir27b promoter-luciferase assay with wild-type and HRE mutant promoters. Hif1α increased luciferase reporter gene expression only from the wild-type promoter but not from the HRE mutant promoter or in control cells, respectively ( Fig. 9w). In the presence of ectopic expression of HIF1α△ODD, the promoters of the neighboring miRNAs mir23b and mir24 did not show increased promoter activity ( Fig. 9 x). Furthermore, Hif1α was specifically associated with the mir27b promoter in the native chromatin of shVhl-transduced NRCs, as shown by Hif1α chromatin immunoprecipitation (ChIP) in nuclear extracts ( Fig. 9 y). The efficiency of pVhl depletion by shVhl and the resulting Hif1α accumulation were confirmed by immunoblotting ( Fig. 9 z). Taken together, these data define MIR27B as a bona fide HIF1α target miRNA.

[0285] Atp5a1 contains a miR27b binding site in the 3'UTR (conserved between humans and mice) ( Fig.10 a), which, once disrupted by site-directed mutagenesis, leads to derepression of miR27b-mediated repression ( Fig.10 b). Consistent with this, ectopic mir27b expression in NRCs resulted in a significant suppression of Atp5a1 mRNA and protein ( Fig.10 c-10e). Although HIF1α upregulated miR27b-3p and miR27b-5p RNA, miR27b-5p had the unique ability to suppress wild-type Atp5a1 UTR reporter gene expression ( Fig.10 b). Treatment of cardiomyocytes with miR27b-5p mimics resulted in a dose-dependent downregulation of Atp5a1 mRNA, whereas miR27b-3p mimics did not ( Fig.10 f). These observations were recapitulated by locked nucleic acid (LNA)-mediated inhibition of miR27b-5p in cardiomyocytes expressing ectopic HIF1α△ODD ( Fig.10 g-10i). LNA specifically targeting miR27b-5p resulted in derepression of HIF1α△ODD-induced Atp5a1 downregulation ( Fig.10 g-10i). Similar results were observed upon T3 stimulation, where inhibition of Atp5a1 was rescued upon simultaneous treatment with miR27b-5p LNA ( Fig.10 j-10m). Therefore, the inhibition of Atp5a1 by miR27b is mediated by miR27b-5p species specifically.

[0286] To determine whether downregulation of Atp5a1 under these conditions affected ATP synthase activity, we measured the ATP regeneration capacity of immunoprecipitated ATP synthase isolated from rat cardiomyocytes ectopically expressing mir27b or shAtp5a1, or upon ectopic HIF1α△ODD expression in combination with mir27b-5p LNA ( Fig.10 As indicated, ectopic mir27b and HIF1αΔODD expression resulted in a significant inhibition of ATP synthase activity, which was rescued by parallel treatment with mir27b-5p LNA ( Fig.10 n, 10o). Inactivation of Atp5a1 also mimicked the effects of ectopic mir27b expression, whereas concomitant overexpression of Atp5a1 with a tagged construct ( Fig.10 p) rescued the decrease in ATP synthase activity when ectopic HIF1α△ODD was expressed ( Fig.10 o). Therefore, ATP synthase activity is highly dependent on the expression level of Atp5a1.

[0287] miR27b-5p inhibition attenuates severe cardiac hypertrophy and dysfunction

[0288] To evaluate whether MIR27B expression is associated with human cardiac pathology, we analyzed MIR27B expression in healthy and diseased human cardiac biopsies. Figure 2 As shown in a, MIR27B expression was elevated in left ventricular biopsies of HCM and AS patients compared with healthy subjects, and thus it was negatively correlated with ATP5A1 expression ( Figure 1 a). We tested the causal relationship between mir27b and Atp5a1 in vivo by delivering AAV9 carrying pre-mir27b (AAV9-fl / fl-mir27b) to Mlc2v-Cre transgenic mice to achieve ectopic mir27b expression specifically in ventricular myocardium. As indicated, ectopic mir27b expression was sufficient to drive cardiac overgrowth, contractile dysfunction, and Atp5a1 mRNA and protein repression 11 weeks after transduction ( Figure 2 b-2h). In addition, with Cre - Compared with the same littermates, the Mlc2v-cre + An increase in the fraction of multinucleated myocytes was observed in the left ventricle of mice, reflecting an increase in endoreplication ( Figure 2 i, 2j and Fig.11 d-11f), and the extent achieved was comparable to that observed in TAC surgery ( Figure 1 i, 1j). The degree of cardiac fibrosis was also increased ( Fig.11These observations, together with our identification of miR27b-5p as a major regulator of Atp5a1 expression ( Fig.10 b, 10f-10p) led us to investigate the function of miR27b-5p in mice displaying severe heart failure, a disease state often associated with ATP synthase inhibition and ATP depletion. C57BL / 6J mice were randomized into two groups that received either sham or TAC surgery and were further subdivided into groups treated with either scrambled LNA (scrLNA) or miR27b-5p LNA ( Figure 2 k). To simulate advanced heart failure in humans, we performed TAC surgery and allowed hypertrophy to develop until severe cardiac dysfunction was detected by echocardiography. LNA therapy was initiated at this time, and echocardiography was performed to monitor disease progression, as shown in the respective figures ( Figure 2 TAC surgery resulted in an increase in aortic blood flow velocity, which is a control for the degree of myocardial overload, whereas sham-operated mice showed normal aortic blood flow ( Fig.11 i). This was accompanied by severe cardiac hypertrophy, as evidenced by increased ventricular weight: 42 days after TAC surgery, the ejection fraction (EF) of mice was significantly reduced ( Figure 2 l-2p and Table 3), which clearly demonstrated body weight ratio and ventricular dilatation and systolic cardiac dysfunction. Based on this observation, each group of mice was subdivided for scrLNA or miR27b-5p LNA treatment. Longitudinal monitoring of disease progression by echocardiography showed that sham-operated mice had no pathological changes. Mice that underwent TAC surgery and were treated with scrLNA showed further decline in cardiac function and heart failure, as evidenced by significant progression of hypertrophy, ventricular dilatation, and decreased cardiac ejection fraction ( Figure 2 l-2p and Table 3). In contrast, TAC mice treated with miR27b-5p LNA showed improved cardiac function and partial reversal of hypertrophic growth ( Figure 2 l-2p and Table 3). Analysis of miR27b-3p and miR27b-5p expression confirmed the specific inactivation of the miR27b-5p species ( Figure 2 q, 2r), which is associated with a decrease in the expression of hypertrophic marker genes compared with mice that underwent TAC surgery and were treated with scrambled LNA ( Figure 2 s) and increased Atp5a1 mRNA and protein expression, and mimicked the expression levels in sham-operated mice ( Figure 2 t, 2u). Notably, in mice that underwent TAC surgery and received miR27b-5p LNA, the stress-induced increase in multinucleation detected by immunofluorescence staining of left ventricular sections from mice that underwent TAC surgery and injected with scrambled LNA was significantly reduced ( Figure 2v, 2w and Fig.11 Similarly, miR27b-5p LNA treatment significantly reduced cardiac fibrosis and mortality in mice undergoing TAC surgery compared with mice injected with scrambled LNA ( Figure 2 x and Fig.11 m, 11n). Thus, pathological stress-induced MIR27B-5p expression and ATP5A1 repression are required to maintain key aspects of pathological cardiac growth in humans and mice.

[0289] Mitochondrial ADP drives purine biosynthesis

[0290] Given that ATP synthase inactivation increases ADP levels within mitochondria, we explored whether ADP could be redirected to MTHFD1L (a mitochondrial rate-limiting enzyme of the 1-carbon pathway that accounts for 70% to 99% of formate produced within the cell) in the absence of ATP synthase substrate competition. MTHFD1L utilizes ADP as a rate-limiting cofactor for the hydrolysis of 10-formyltetrahydrofolate (CHO-THF) to formate (Figure 3a). To test this, we measured formate, mitochondrial ATP, and ADP levels in genetic gain- and loss-of-function settings of Hif1α, miR27b, Atp5a1, and Mthfd1l (Figures 3b, 3c, Fig.12 a-12h). Increased formate production and ADP:ATP ratio were directly associated with ectopic Hif1α or miR27b expression and shRNA-mediated knockdown of Atp5a1 (Figures 3b, 3c). Next, we performed metabolomics studies in a similar setting as above to investigate the metabolic link between activation of the HIF1α-MIR27B-ATP5A1 axis and increased levels of multinucleation and growth of cardiomyocytes (Figure 3d). Significant ectopic Hif1α, miR27b or shAtp5a1 expression led to increased levels of glucose and glycolytic intermediates (dihydroxyacetone phosphate, 3-phosphoglycerate), indicating increased glucose uptake and glycolysis. In addition, increased levels of serine and glycine, intermediates of the purine biosynthesis pathway (5-phosphoribose, FGAR), and purine and pyrimidine derivatives (inosine, xanthine, dUTP, GTP, uridine) were observed. In contrast, concomitant inactivation of miR27b-5p, depletion of Mthfd1l, or ectopic ATP5A1 expression partially reversed these effects (Fig. 3d). Moreover, ectopic expression of MTHFD1L alone was not sufficient to induce the de novo purine biosynthesis pathway, supporting the view that mitochondrial ADP is preferred as a substrate for ATP synthase and that the induction of mitochondrial formate biosynthesis is highly dependent on the inhibition of ATP5A1 (Fig. 3d). Similar results were observed with T3, which resulted in a high dependence on miR27b for growth (Fig. Fig.13a) Production of formate ( Fig.13 b) and ADP / ATP increase ( Fig.13 c). LC-MS-based metabolome analysis showed that the production of purine and pyrimidine derivatives increased with miR27b expression ( Fig.13 d).

[0291] Thus, redirection of ADP links energy tradeoffs to stress-induced biosynthetic pathways.

[0292] Purine is essential for nucleic acid synthesis, endoreduplication, and cell growth. Its de novo synthesis can be traced back to glucose that enters the cell and undergoes glycolysis to form 3-phosphoglyceride (3-PG), and is further metabolized through the serine biosynthetic pathway to generate serine and (indirectly) glycine, which then serves as a key 1-carbon donor by incorporating its carbon into the purine ring (Figure 3a). Since the carbon atoms incorporated into the purine ring are essentially traceable to glucose carbons, we tracked the flux of carbon into the nucleic acid purine ring by labeling glucose, serine, and glycine, respectively (Figure 3e). As shown, increased incorporation of carbon atoms from glucose, serine, and glycine was observed in nucleic acid fragments of cells ectopically expressing HIF1α△ODD, miR27b, or shAtp5a1 (Figure 3e), while simultaneous ectopic MTHFD1L expression did not significantly increase the contribution of labeled carbon to nucleic acid fragments (Figure 3e), which is consistent with the metabolome profile obtained (Figure 3d). Similar effects were observed in the presence of T3-induced cell growth and inactivation of miR27b-5p ( Fig.13 e) These data suggest that the entire upstream network affects the crosstalk between ATP5A1 and MTHFD1L in regulating pathology-induced de novo nucleic acid synthesis.

[0293] Finally, we determined whether similar changes in metabolite profiles could be detected in left ventricular biopsies from sham- or TAC-operated mice treated with scrambled LNA (scrLNA) or miR27b-5p LNA ( Figure 2 k-2p). Fig.14 As shown in a, metabolite changes observed in the left ventricle of the heart were very similar to those observed in vitro, including increases in purine precursors such as N-formylglycinamide ribonucleotide (FGAR) and 5-formamidoimidazole-4-carboxamide nucleotide (FAICAR) in mice treated with TAC and scrLNA compared to animals treated with TAC and miR27b-5p LNA or mice treated with sham and scrLNA. In addition, the levels of the purines xanthine and inosine were significantly lower in mice treated with TAC and miR27b-5p compared to mice treated with TAC and scrLNA ( Fig.14a). Hierarchical cluster analysis showed that the metabolic signature of left ventricular biopsies from mice that underwent TAC surgery and were injected with miR27b-5p LNA was altered compared with mice that underwent TAC surgery and were injected with scrLNA, but was comparable to that of mice that underwent sham surgery and were treated with scrLNA and miR27b-5p LNA ( Fig.14 b). In particular, left ventricular biopsies from mice that underwent TAC surgery and were injected with miR27b-5p LNA showed lower levels of free fatty acids and other lipid species compared to TAC-scrLNA control mice ( Fig.14 a). Therefore, we also investigated the liposomes in the above in vivo samples ( Fig.15 a-15g). Principal component analysis (PCA) showed that the left ventricle of mice that underwent TAC surgery and were injected with scrLNA had a unique lipid signature compared with mice that underwent TAC surgery and were injected with miR27b-5p LNA ( Fig.15 a). Liposomes from hearts that underwent sham or TAC surgery and were treated with scrLNA partially overlapped but were clearly separated along the first principal component (PC1), whereas lipids from hearts that underwent sham or TAC surgery and had reduced miR27b-5p expression levels were clearly separated along the second principal component (PC2) ( Fig.15 A closer look at the lipid composition revealed that left ventricular biopsies from mice that underwent TAC surgery / injection with miR27b-5p LNA indeed showed the highest content of lipids containing 6 double bonds (db), while TAC scrLNA samples clearly highlighted 2db, 4db, and lipids containing 34 and 36 carbon atoms ( Fig.15 d, 15e).

[0294] Analysis of the results obtained by subtracting the average molar percentage abundance of lipid species in control mice from the abundance of individual lipid species in TAC-operated mice revealed that TAC samples were enriched in arachidonic acid (20:4) and linoleic acid (18:2) ( Fig.15 f). Strikingly, lipids containing docosahexaenoic acid (22:6) accumulated in the left ventricle of TAC-operated mice in which miR27b-5p expression was suppressed ( Fig.15 g). Consistent with this result, free docosahexaenoic acid was also increased in the non-targeted metabolic analysis ( Fig.14a). In summary, comprehensive analysis of cardiac lipid profiles revealed a correlation between protection against pressure overload-induced left ventricular growth and an enrichment in polyunsaturated lipids, particularly docosahexaenoic acid-containing lipids, which have been shown to be cardioprotective. On the other hand, the increase in hypertrophy was associated with a significant upregulation of lipids containing 34- and 36-carbon fatty acids, suggesting reduced fatty acid oxidation. This is consistent with a greater oxidative phenotype in the hearts of mice that underwent TAC surgery and were treated with miR27b-5p LNA compared to mice that underwent TAC surgery and were treated with scrLNA ( Fig.14 a), Lipid catabolism was significantly enhanced in mice treated with miR27b-5p LNA, as evidenced by the enrichment of long-chain fatty acids in TAC-operated hearts treated with scrLNA compared with TAC-operated hearts treated with miR27b-5p LNA ( Fig.15 In addition, increased expression of lipid catabolism mediators was observed in TAC-operated and miR27b-5p LNA-treated hearts (compared to TAC-operated and scrLNA-treated mice), which corresponds to increased palmitate oxidation capacity in TAC-operated and miR27b-5p LNA-treated hearts ( Fig.15 h, 15i).

[0295] In summary, these analyses revealed a unique lipid signature of hearts that underwent TAC surgery and were treated with miR27b-5p LNA, characterized by a significant upregulation of cardioprotective docosahexaenoic acid-containing lipids and an enhanced fatty acid oxidation capacity.

[0296] ATP synthase controls cardiomyocyte endoreplication and pathological growth

[0297] Cardiomyocyte endoreplication precedes pathological cardiac overgrowth (Ahuja, P. et al., 2007, Physiol Rev, 87, 521-544). To understand whether the identified axis indeed promotes cardiomyocyte multinucleation and growth through ADP, the present inventors mimicked miR27b-mediated ATP5A1 inhibition by treating primary cardiomyocytes with oligomycin, an inhibitor of F0 subunit ATP synthase (Shchepina, LA et al., 2002, Oncogene, 21, 8149-8157) or stimulating primary cardiomyocytes with ADP (Hu, J. et al., 2014, Cell Death Dis, 5, 1424). Fig.16 As shown in a-16d, ADP levels were indeed increased in cells treated with oligomycin or ADP. Next, the inventors quantified the fraction of multinucleated cells by immunofluorescence staining with DAPI and skeletal muscle α-actin ( Fig.16e-16h), and cardiac hypertrophy quantified by cell size ( Fig.16 i, 16j), the sufficiency of oligomycin or ADP-induced endoreplication and multinucleation was assessed.

[0298] To better define the underlying mechanisms, the present inventors analyzed cardiomyocyte ploidy and cell size in gain- and loss-of-function settings of Hif1α, miR27b, Atp5a1, and Mthfd11 ( Figure 4 A-4i and Fig.17 a-17h). Ectopic HIF1α, mir27b, ​​or shAtp5a1 expression was sufficient to increase the number of multinucleated polyploid cells, as shown by imaging-coupled flow cytometry and flow cytometry of DNA stained with propidium iodide (PI). Figure 4 a-4f), which is a simultaneous miR27b-5pLNA-mediated inactivation ( Figure 4 a, 4b), ectopic ATP5A1 expression ( Figure 4 c, 4d) or depletion of Mthfd11 by co-transduction of lentivirus expressing shMthfd11 ( Figure 4 To directly visualize endoreduplicating multinucleated cells, cardiomyocytes were stained to visualize phosphorylated histone 3 at serine 10 (p-histone H3) and imaged by confocal microscopy ( Fig.17 a-17h). Phospho-histone H3 marks condensed chromosomes, which are characteristic of nucleated cells. Consistent with the flow cytometry data, ectopic HIF1α△ODD expression resulted in an increase in nuclei stained with phospho-histone H3, which was rescued by parallel inhibition of miR27b-5p with LNA ( Fig.17 In addition, mir27b overexpression or Atp5a1 inhibition also led to an increase in the number of nucleated cells compared with the corresponding controls ( Fig.17 c, 17d). shRNA-mediated inhibition of Mthfd1l resulted in effective depletion of its mRNA and protein ( Fig.17 e, 17f), and resulted in phosphorylated histone H3 staining comparable to that of control cells ( Fig.17 g, 17h). Notably, simultaneous expression of ectopic ATP5A1 and mir27b or co-transduction of NRC with shMthfd1l and shAtp5a1 lentiviruses also reduced the broad pattern of phosphorylated histone H3 staining, as observed when ectopic expression of mir27b or shAtp5a1 alone was observed ( Fig.17 c-17h). In order to verify that the increase in de novo purine biosynthesis and multinucleation is directly related to cell growth, the inventors conducted a leucine incorporation experiment under the same treatment conditions. Figure 4As shown in g-4i, ectopic HIF1α△ODD, mir27b expression or Atp5a1 knockdown led to increased leucine incorporation (indicating increased protein synthesis and cell growth), which was not observed in the presence of simultaneous mir27b-5p inactivation ( Figure 4 g) or not when Atp5a1 was ectopically expressed ( Figure 4 h). Consistent with the critical requirement for MTHFD1L in purine biosynthesis, the proportion of multinucleated cells decreased when both MTHFD1L and ATP5A1 were depleted ( Figure 4 e, 4f), and pathological cell growth was also reduced ( Figure 4 i). Our data therefore support the idea that reprogramming of the metabolic environment is sufficient to drive cardiomyocyte endoreplication, leading to multinucleation and cell growth.

[0299] MTHFD1L is a key regulator of pathological cardiac growth

[0300] To confirm that MTHFD1L affects pathological cardiac hypertrophy, the present inventors administered Mlc2v-cre to sham-operated or TAC-operated mice. - and Mlc2v-cre + Mice were injected with AAV9 containing short hairpin RNA targeting MTHFD1L (AAV9-fl / fl-shMthfd1l) ( Figure 5 a). Compared with previous TAC data ( Figure 1 i, 1j) are consistent, Mlc2v-cre - Multinucleation was significantly increased in mice, as quantified by immunofluorescence staining ( Figure 5 b, 5c and Fig.18 a) Along with stress-induced endoreplication, Mlc2v-cre - Mice that underwent TAC surgery developed pathological cardiac hypertrophy and systolic dysfunction, which was different from that of sham-operated Mlc2v-cre mice. - Compared with mice, the left ventricular weight:body weight ratio was increased, the left ventricular diastolic diameter (LVId) was enlarged, the genes of hypertrophy markers were increased, and the ejection fraction was reduced ( Figure 5 d-5g, Fig.18 b-18d and Table 4). Strikingly, similarly treated Mlc2v-cre - Compared with the same littermates, Mlc2v-cre + The percentage of multinucleated cells in mice was significantly reduced ( Figure 5 b, 5c and Fig.18 a, 18e, 18f). At the same time, cardiac hypertrophy, fibrosis and systolic dysfunction were also significantly reduced ( Figure 5 d-5g, Fig.18b, 18g, 18h and Table 4). qRT-PCR analysis and immunoblotting of Mthfd1l expression showed that AAV9-fl / fl-shMthfd1l transduction ( Figure 5 h and Fig.18 d), Mthfd1l produced full suppression at both RNA and protein levels, consistent with resistance to TAC-induced cardiac overgrowth and contractile dysfunction.

[0301] TAC-operated Mlc2v-cre - and Mlc2v-cre + Consistent with the accumulation of HIF1α in the heart of WT mice, Atp5a1 expression was inhibited, leading to AMPK phosphorylation at Thr172 and ACC hyperphosphorylation ( Figure 5 h). Consistent with the fact that Mthfd1l inhibition was sufficient to prevent the increase in multinucleation caused by TAC-mediated pressure overload-driven cardiac metabolic endoreduplication, multinucleation, overgrowth, fibrosis, and dysfunction caused by ATP5A1 downregulation ( Figure 1 k and Figure 8 a-8i) can also be prevented by parallel inactivation of Mthfd1l in vivo ( Figure 5 i-5o, Fig.18 i-18q and Table 5). Mlc2v-cre was co-injected with AAV9-fl / fl-shAtp5a1 and AAV9-fl / fl-shMthfd1l. + Mice showed no increase in multinucleated cells ( Figure 5 j, 5k and Fig.18 i-18k), and ventricular size ( Figure 5 l, 5m and Figure 181), left ventricular weight: body weight ratio ( Figure 5 n), hypertrophy marker gene expression ( Fig.18 m) and normal left ventricular systolic function ( Figure 5 o and Table 5), although when Mthfd1l was simultaneously inhibited ( Fig.18 o) Atp5a1 is effectively inhibited ( Figure 5 p and Fig.18 n), indicating that Mthfd1l acts downstream of Atp5a1. The levels of cardiac fibrosis were comparable between the two groups ( Fig.18 p, 18q). Thus, ATP5A1 inhibition and the resulting redirection of ADP to MTHFD1L, and the consequent increase in purine biosynthesis, drives cardiac metabolic endoduplication and multinucleation, thereby promoting pathological cardiac growth.

[0302] ATP5A1 integrates metabolic and growth signals to drive pathological growth

[0303] AMPK activation has been shown to inhibit the tumor suppressor retinoblastoma protein (Rb) through phosphorylation at Ser804. Rb restricts DNA replication and cell cycle progression from G1 to S by sequestering and inhibiting E2F transcription factors (E2F-DP, composed of dimeric E2F proteins and dimerization partner (DP) proteins). Rb phosphorylation leads to the release and derepression of E2F transcription factors from the E2F-DP complex, ultimately leading to E2F target gene induction and cell cycle reentry. Given that the HIF1α-miR27b-ATP5A1-MTHFD1L axis creates a metabolic environment in postmitotic adult cardiomyocytes that allows cell cycle reentry and endomitosis, the inventors explored the possible synergy of metabolic and growth factor signaling in cardiac pathological hypertrophy.

[0304] First, the inventors confirmed the direct interaction between AMPK and Rb by co-immunoprecipitation of AMPK and Rb. To this end, the AMPKα subunit was ectopically expressed in cardiomyocytes and then immunoprecipitated. The pull-down product showed that AMPKα co-precipitated with phosphorylated Rb ( Figure 6 a, 6b). The present inventors confirmed this interaction by pull-down of endogenous AMPK in cells expressing ectopic HIF1αΔODD. As previously described, AMPK was immunoprecipitated with phosphorylated Rb in cardiomyocytes ectopically expressing HIF1αΔODD, but not when AMPK was simultaneously inhibited with compound C (CC), a potent AMPK inhibitor ( Figure 6 c, 6d).

[0305] Having demonstrated a direct interaction between AMPK and phosphorylated Rb, the inventors next assessed whether Rb was hyperphosphorylated in our human biopsies and various mouse models ( Figure 6 Indeed, hyperphosphorylation of Rb was detected in lysates of left ventricular biopsies from mice that underwent TAC surgery and were injected with scrRNA ( Figure 6 e), and ectopic mir27b expression ( Figure 6 f) and Atp5a1 depletion ( Figure 6 g) Phosphorylation of AMPK at Thr172 under these conditions as described previously ( Fig.11 and Figure 2 h, 2u). After TAC surgery, LNA targeting miR27b-5p was injected ( Figure 6 e) or the left ventricle of mice transduced with AAV9 carrying shRNAs against Mthfd1l and Atp5a1 or against Mthfd1l alone was protected from pRb induction ( Figure 6 h, 6i). Compared with the mouse experiments and the observation of AMPK Thr172 phosphorylation ( Figure 1 c) Consistently, immunoblotting of ventricular biopsy lysates from AS and HCM patients revealed a similar increase in phosphorylated Rb expression ( Figure 6 j). In summary, pRb is a downstream target of phosphorylated AMPK in the presence of cardiac metabolic endoreduplication driving the HIF1α-MIR27B-ATP5A1 axis.

[0306] To investigate whether the predicted release of E2F1 following Rb hyperphosphorylation would result in enhanced transcriptional activity of E2F1, we performed qRT-PCR analysis to detect changes in the RNA levels of E2F1 target genes (cyclins A1, A2, D1, E1 (Ccnal, Ccna2, Ccnd1, Ccne1) and cyclin-dependent kinase 1 (Cdk1)) in left ventricular samples of mice and human cardiac biopsies treated with the above conditions ( Figure 6 These gene expression analyses confirmed activation of the E2F pathway in vivo downstream of phosphorylated AMPK-mediated Rb inhibition in mice and in patients with AS and HCM ( Figure 6 k-6n). E2F luciferase reporter gene assays performed in NRC further confirmed E2F transcriptional activity under ectopic expression of HIF1α△ODD, mir27b, ​​or Atp5a1 depletion ( Figure 6 o, 6p). Finally, to functionally evaluate the effects of cell cycle regulators on endomitosis and multinucleation in cardiomyocytes, the present inventors inactivated Ccnd1 (cyclin D1) and Ccne1 (cyclin E1), two key downstream components of Rb activation in cardiomyocytes expressing ectopic HIF1α△ODD. As demonstrated, inactivation of Ccnd1 and Ccne1 inhibited HIF1α-mediated endomitosis, multinucleation, and hypertrophy ( Fig.19 a-19f). In contrast, inactivation of the cell cycle inhibitor Cdkn1b (p27 / Kip1) is sufficient to induce endomitosis, multinucleation, and pathological growth in cardiomyocytes ( Fig.19 g-19k). In summary, the inventors have demonstrated that cardiac endoreduplication and multinucleation require simultaneous activation of de novo purine biosynthesis (promoted by the identified HIF1α-MIR27B-ATP5A1-MTHFD1L axis) and cell cycle activation by E2F1. This is reflected in the fact that depletion of Mthfd1l combined with Atp5a1 inhibition is sufficient to induce AMPK activation and E2F transcription ( Figure 6 h, 6i, 6l, 6m), but failed to induce cardiac metabolic endoreplication ( Figure 5 b, 5c, 5j, 5k).

[0307] Materials and methods

[0308] Animal breeding and care

[0309] Hif1αfl / fl mice were from Randall S. Johnson (University of California, San Diego, USA), and Vhl fl / fl mice were kindly provided by Rudolf Jaenisch (Massachusetts Institute of Technology, USA). Myosin light chain (Mlc) 2v-Cre (Chen, J. et al., 1998, Development, 125, 1943-1949) lines were from Ju Chen (University of California, San Diego, USA). Each ventricle-specific mouse line described in this manuscript was generated by crossing loxP-flanked Hif1α (Hif1αfl / fl) (Ryan, HE et al., 2000, Cancer Res, 60, 4010-4015) or Vhl (Vhl fl / fl) (Haase, VH et al., 2001, Proc Natl Acad Sci USA, 98, 1583-1588) mice with myosin light chain Mlc2v-Cre transgenic mice. The data presented represent the results of studies on male mice of C57BL / 6J background, 3-20 weeks old. By 3-20 weeks, the inventors refer to the entire duration of the animal experiments. AAV9 virus was administered to 3-week-old mice. Since AAV9 vectors have a lag period of approximately 6-10 weeks before reaching maximum expression, surgery was performed 9-11 weeks after AAV9 administration, and the hearts were harvested at least 11 weeks later, as shown in FIG. Figure 1 Experimental curves in k, 2b, 2k, and 5a are shown. In TAC experiments, mice were 10-12 weeks old at the start of the experiment. Only mice of similar age (+ / -1 week) were used in the corresponding experiments. In experiments with Mlc2v-cre mice, littermates and mice of similar age (+ / -1 week) were used. After baseline echocardiography, mice were randomized into groups and subjected to AAV injection, LNA delivery, and echocardiography. In experiments including TAC surgery, the experiment was kept blind on baseline echocardiography before surgery. All mice were housed in a specific pathogen-free facility at the MRC Clinical Science Center (Imperial College London), the Institute of Molecular Health Sciences in Zurich (ETH Zurich), and / or the Cardiovascular Assessment Facility (CAF), Department of Medicine, University of Lausanne. Maintenance and animal experiments were in accordance with the guidelines of the Swiss Federal Veterinary Office (BVET).

[0310] Human and mouse ventricular biopsies

[0311] Human cardiac biopsies and clinical data were generously provided by Samuel Sossalla (Georg-August University Göttingen and DZHK, Göttingen, Germany) and Sebastian Stehr (University Hospital Leipzig, Germany). Human HCM and aortic stenosis biopsies were performed in accordance with the requirements of the local ethics committee, and written informed consent was obtained from all subjects before inclusion. Myocardial samples were obtained from patients with severe aortic stenosis who underwent aortic valve replacement and Morrow resection of hypertrophic left ventricular septum. Only patients without significant aortic regurgitation and preserved systolic function were included. Human left ventricular biopsies from patients with HCM were obtained from the left ventricular papillary muscle of transplanted hearts. Myocardial samples were obtained directly in the operating room during surgery and immediately washed in precooled cardioplegia solution (110 mM NaCl, 16 mM KCI, 16 mM MgCl2, 16 mM NaHCO3, 1.2 mM CaCl2, 11 mM glucose) and then snap-frozen in liquid nitrogen. Healthy heart samples were obtained from the left ventricle of donor hearts. The weight of the samples was approximately 20-150 mg. Clinical data related to these subjects can be found in previous publications. 16 .

[0312] Transaortic ligation (TAC) was performed on 9-14 week old mice by constriction of the descending aorta as described previously (Kassiri, Z. et al., 2005, Circ Res, 97, 380-390). Mice were monitored for up to 9 weeks after surgery, and their cardiac dimensions and function were determined by echocardiography. Figure 2 As described in the previous study, the in vivo miRCURY LNA Power inhibitors were injected intraperitoneally (ip) into C57BL / 6J mice at a dose of 10 mg / kg starting from day 49 after surgery for 4 consecutive days. The following in vivo miRCURY LNA Power inhibitors were purchased from Exiqon: i-mmu-miR-27b-5p (199900). i-Cel-control_inh (199900) was used as a scrambled control LNA.

[0313] In vivo transthoracic ultrasound imaging

[0314] Transthoracic echocardiography was performed using the MS400 (18–38 MHz) probe of a Vevo2100 color Doppler ultrasound system (VisualSonics). Mice were lightly anesthetized with 1% to 1.5% isoflurane to maintain a heart rate of 400–550 beats per minute. Mice were placed in a dorsal position on a heated platform at 37°C to maintain body temperature. Hair was removed using a topical depilatory, and ultrasound gel was used as a coupling medium between the transducer and the skin. The heart was imaged in 2D mode in the parasternal long-axis view. From this perspective, the M-mode cursor was perpendicular to the posterior wall of the left ventricle at the level of the ventricular septum and papillary muscles. The diastolic and systolic diameters of the ventricular septum (IVS; d and IVS; s), the diastolic and systolic diameters of the posterior wall of the left ventricle (LVPW; d and LVPW; s), and the end-diastolic and end-systolic left ventricular internal diameters (LVID; d and LVID; s) were measured. Measurements were performed in three independent M-mode images and averaged. Left ventricular fractional shortening (%FS) and ejection fraction (%EF) were also calculated. Fractional shortening was assessed from the M-mode according to the percentage change in left ventricular end-diastolic and end-systolic diameters. %EF was derived from the formula (LV vol;d-LV vol;s) / LV vol;d×100; At the end of the experiment, the animals were sacrificed and the ratio of heart weight to body weight was measured.

[0315] Isolation and Maintenance of Primary Neonatal Rat Cardiomyocytes

[0316] Primary neonatal rat cardiomyocytes (NRCs) were isolated using the manufacturer's recommended neonatal heart isolation kit (130-098-373, Miltenyi Biotec). The isolated cells were pre-cultured with plate culture medium (65% DMEM, 16% M199, 10% fetal calf serum (FCS), 5% horse serum (HS), 2% glutamine, and 1% penicillin / streptomycin (P / S)) for 1.5 h to deplete fibroblasts. NRCs were cultured in plate culture medium on 3 cm culture dishes (Nunc) coated with type I collagen (Advanced Biomatrix). 24 h after NRC isolation, the plate culture medium was changed to maintenance medium (88% DMEM, 9% M199, 1% HS, 2% glutamine, and 1% P / S). Cardiomyocytes were treated with 3,3',5-triiodo-L-thyroxine (T3, T5516, SigmaAldrich) at a concentration of 15 nM for 6 days. NRCs were stimulated with exogenous ADP (A2754, Sigma Aldrich) at a concentration of 10 μM for 3 days. Oligomycin A (75351, Sigma Aldrich) and AMPK inhibitor compound C (CC; 171260, Sigma Aldrich) were applied at a concentration of 20 nM for 2 days and 5 μM for 24 h, respectively. NRCs were randomly selected for treatment on the second day after isolation.

[0317] Isolation of adult mouse cardiomyocytes

[0318] The left ventricle of adult mouse heart was cut into 1 mm 3 The biopsy samples were digested with 1000U of type II collagenase (17101-015, Gibco) in HBSS at 37°C for about 42h while rotating. The appropriate concentration of isolated adult cardiomyocytes was centrifuged at 600rpm for 1min onto a gelatin-coated microscope slide using a cytospin (SCA-0030, Shandon Southern).

[0319] Human cardiomyocyte culture

[0320] Human induced pluripotent stem cell-derived human cardiomyocytes (iPSC-CMs) were purchased from Cellular Dynamics International (CMC-100-010-001) and cultured according to the manufacturer's recommendations. These cells showed clear sarcomere organization, as shown by striations. In addition, these cells were terminally differentiated because they did not proliferate and could not be passaged. Gene expression analysis showed that iPSC-CMs expressed more than 200 cardiac genes, with expression profiles of α-actin and cardiac troponin T similar to those of adult heart tissue. The cells began to beat spontaneously 24-48h after thawing and formed an electrically connected, synchronously beating syncytial layer. When these cells formed synchronously beating syncytia, they were considered suitable for study. After 6-7 days of culture, cells were randomly selected for lentiviral transduction and experiments were performed on day 10.

[0321] Isolation of mitochondria

[0322] Mitochondria were isolated using a mitochondrial isolation kit for cultured cells (ab110171, Abeam). Briefly, 1.2 × 10 6 NRCs were added and the cells were then scraped. After a freeze-thaw step to weaken the cell membrane, the cells were resuspended in 5 mg / ml protein in reagent A and incubated on ice for 10 min. The cells were homogenized 30 times in a Dounce homogenizer and centrifuged at 1000g for 10 min at 4°C. The pellet was resuspended in the same volume of reagent B as reagent A, and the rupture and centrifugation were repeated. The supernatants obtained after the two centrifugation steps were combined and centrifuged at 12000g for 15 min at 4°C. The pellet was resuspended in 80 μL of reagent C supplemented with protease inhibitors and stored at -80°C. Mitochondrial ADP:ATP was quantified using the manufacturer's recommended EnzyLight ADP / ATP ratio assay kit (ELDT-100, Bioassay Systems).

[0323] Lentivirus production and infection

[0324] HEK-293T cells were transfected with polyethyleneimine (PEI) transfection reagent at 80% to 90% confluency. 10 μg of transgene, 7.5 μg of pMD2.G and 6.5 μg of psPAX2 were mixed with 2 ml of serum-free DMEM and 45 μg of PEI in each 10 cm dish. After 10 min of incubation at room temperature (RT), the DNA / PEI complex was slowly added to the cells cultured in DMEM containing 0.5% FCS and L-glutamine. The medium was replaced with NRC maintenance medium 4 h after transfection. The lentivirus was collected 48 h after transfection and stored at -80°C. NRCs were infected 20 h after isolation and incubated overnight at 37°C in 5% CO2.

[0325] AAV9 constructs

[0326] To generate adeno-associated viral constructs, shRNA targeting Mthfd11 was cloned into the pSico vector, where the U6 promoter-driven shRNA expression was controlled in a Cre-dependent manner. shRNA targeting Mthfd11 was designed using the online software pSico-Oligomaker (MIT, version 1.5). The following shRNA sequences were used:

[0327] AAV9-fl / fl-sh Mthfd1l,

[0328] Sense (SEQ ID NO 003):

[0329] TGAATGGTGTCAGAGAATTTTTCAAGAGAAAATTCTCTGACACCATTCTTTTTTC,

[0330] Antisense (SEQ ID NO 004):

[0331] TCGAGAAAAAAGAATGGTGTCAGAGAATTTTCTCTTGAAAAATTCTCTGACACCATTCA.

[0332] After in vitro validation of shRNA knockdown efficiency by inducing Cre-mediated recombination and activation of shMthfd1l expression with Adeno-Cre (Cat No ADV-005, Cell Biolabs), the region containing the U6 promoter, shRNA, and TATA-lox sites of the pSico construct was amplified and ligated into the Nhel / Xhol linearized AAV-bGH(+) vector. All other viruses were designed and engineered by Targeted Transgenesis. AAV9 virus was injected at 1.2×10 per kg body weight. 13 The concentration of 100 genomic copies (GC) was injected into 3-week-old Mlc2v-cre - and Mlc2v-cre + into the tail vein of mice.

[0333] In vitro administration of locked nucleic acids (LNA), miRNA mimics, and siRNA

[0334] miRCURY LNA Power inhibitors were added directly to the cell culture medium at a final concentration of 50 nM, and fresh LNA was added every two days. The following miRCURY LNA Power inhibitors were purchased from Exiqon: i-mmu-miR27b-5p (4101712-101). Negative control A (199006-101) was used as a non-targeting LNA.

[0335] The miRIDIAN microRNA mimics were transfected into NRCs using Lipofectamine 2000 (Invitrogen). In each well of a 96-well plate, 0.4 μL of Lipofectamine 2000 was mixed with 25 μL of OptiMEM (Invitrogen). After 5 min of incubation at room temperature, the mixture was added to an Eppendorf tube containing 6.25 nM or 12.5 nM miRNA mimics in 50 μL of OptiMEM and incubated at room temperature for 20 min to form a complex. 50 μl of the complex was added to cells cultured in 100 ml of culture medium without antibiotics. The culture medium was replaced at 4 h after transfection, and the cells were collected at 48 h after transfection. The following miRIDIAN microRNA mimics were purchased from Dharmacon: mmu-miR27b-3p (C-310380-05-0005), mmu-miR27b-5p (C-310810-01-0005). miRIDIAN microRNA mimic negative control #1 (CN-001000-01) was used as a negative control.

[0336] siRNA was transfected into NRC at a final concentration of 50 nM using DharmaFECT 1 transfection reagent (Dharmacon) as recommended by the manufacturer. Gene expression was analyzed 72 h after transfection. The following ON-TARGETplus SMARTpool siRNAs from Dharmacon were used: Ccnd1 (L-089285-02-0005), Ccne1 (L-101575-02-0005), Cdkn1b (L-090938-02-0005). Non-targeting siRNA pool (D-001810-10-05) was used as a control.

[0337] Transient transfection

[0338] Two days after isolation, pCMV6 MTHFD1L (RC223034, Origene) or pEBG-AMPK 1-312 (#27632, addgene) was transiently transfected into primary neonatal rat cardiomyocytes. Cells were collected and analyzed 48 h after transfection.

[0339] Plasmid construction

[0340] As previously described (Troilo, A. et al., 2014, EMBO Rep, 15, 77-85), the pLenti-HIF1α△ODD puro lentiviral expression vector was generated by subcloning the HIF1α△ODD fragment from the pcDNA3-HA-HIF1αAODD (401-603) plasmid (Huang, LE et al., Proc Natl Acad Sci USA, 95, 7987-7992) into the pLenti-pgk puro vector. The plenty-pgk puro empty vector was used as the corresponding control. The miR27b overexpression construct was generated by amplifying the precursor mir27b sequence and flanking sequence 158bp at both ends of the mir27b precursor transcript in mouse genomic DNA. The sequence was cloned into the pLKO.1CMV puro construct provided by A.Ittner (ETH Zurich) using EcoRI and Sail restriction sites. The empty pLKO.1CMV puro construct was used as a control vector.

[0341] Generation of miRNA promoter-luciferase constructs

[0342] Amplified 1.0kb (kb) fragments of mir23b, mir24-1 and mir27b promoters from mouse genomic DNA and cloned into pGL3 luciferase reporter gene vector (Stratagene) between Xhol and Hindlll restriction sites. The HRE mutation in the mir27b promoter is produced by recombinant PCR (Elion, EA et al., 2007, CurrProtoc Mol Biol, Chapter 3, Unit 3 17). Designed the sense and antisense primers with HRE mutation, used to increase the 5' and 3' mutation regions of the mir27b promoter respectively. Subsequently, the 5' and 3' products produced by each PCR reaction were mixed in a ratio of 1: 1, and the primers at the ends of the 5' and 3' targeting promoters were used to increase the entire fragment. The wild-type construct and HRE mutation in the mir27b promoter were confirmed by DNA sequencing (Microsynth).

[0343] Generation of ATP5A1 3'UTR luciferase construct

[0344] The 3'UTR of Atp5a1 was amplified from mouse cDNA and cloned into the pmirGLO dual luciferase miRNA target expression vector (Promega). Mutations in the mir27b binding site on the 3'UTR of Atp5a1 were generated by recombinant PCR. Sense and antisense primers with mutations in the mir27b binding site were generated and used to amplify the 5' and 3' mutant regions of the 3'UTR, respectively. Subsequently, the 5' and 3' products generated by the respective PCR reactions were mixed in a 1:1 ratio, and the entire sequence was amplified using primers targeting the 5' and 3' ends of the Atp5a1 3'UTR. The mutations in the mir27b binding site in the 3'UTR of Atp5a1 were confirmed by sequencing (Microsynth).

[0345] shRNA knockdown of Mthfd1l

[0346] shRNA targeting Mthfd1l was designed using the online software BLOCK-iT RNAi Designer (Life Technologies) and compared to the rat genome using BLAST. The shRNA was cloned into the pLKO.1 vector. The sense and antisense oligos were resuspended in annealing buffer (100 mM NaCl, 50 mM HEPES, pH 7.4) to a concentration of 20 μM. 5 μL of the sense and antisense oligos were mixed and annealed by incubating them in a beaker with boiling water and then cooled to room temperature. The annealed oligos were ligated into the pLKO.1 vector between the Agel and EcoRI restriction sites. 50 ng of vector, 200 ng of annealed oligos, 1 μL of T4 DNA ligase were mixed with 1 μL of 10x ligation buffer and the final volume was brought to 10 μL with PCR-grade water. The ligation reaction was incubated overnight at 16°C and 2 μL of the ligation reaction was transformed into competent Stbl3 bacteria by heat shock transformation. Colonies were screened for shRNA insertion by restriction digestion using NdeI and BamHI, and positive clones were confirmed by DNA sequencing (Microsynth).

[0347] Lentivirus and expression constructs

[0348] For knockdown by lentiviral shRNA, the following TRC pLKO.1 shRNA vectors were used: Atp5a1 (shAtp5a1, TRCN0000076239), Hif1α (shHif1α, TRCN0000232220), and Vhl (shVhl, TRCN0000436052). The pLKO.1 vector containing non-silencing shRNA (nsRNA; SHC002, Sigma) was used as a control. pLenti ATP5A1 (RC214840L1) and pCMV6 MTHFD1L (RC223034) plasmids were from Origene. pEBG-AMPKαl (1-312) was a gift from Reuben Shaw (Addgene plasmid #27632).

[0349] RNA isolation, reverse transcription and qRT-PCR

[0350] Samples were collected in Trizol (Invitrogen) and total RNA was isolated according to the manufacturer's recommendations. According to the manufacturer's instructions, 750 ng RNA was reversely transcribed into cDNA using RNA to cDNA EcoDry Premix (random hexamer) kit (Clontech, Cat No 639545). According to the manufacturer's recommendations, iTaq Universal SYBR Green Supermix (Biorad, Cat No 1725121) was used to set real-time quantitative PCR (qRT-PCR) reactions and it was carried out on a PikoReal real-time PCR machine (Thermo Scientific). Ct values ​​were normalized to housekeeping gene Hprt1. qRT-PCR primer sequences are shown in Table 6.

[0351] To assess mature miRNA levels, 10 ng of total RNA was transcribed into cDNA using the TaqMan MicroRNA Reverse Transcription Kit (4366596, Applied Biosystems) according to the manufacturer's recommendations. qRT-PCR was performed using TaqMan 2×Universal PCR Master Mix (4304437, Applied Biosystems) according to the manufacturer's instructions and performed on a DNA Engine Opticon 2 (Bio-Rad). Ct values ​​were normalized to housekeeping genes snoRNA (rat) or snoRNA202 (mouse). The following primers from Thermo Fisher Scientific were used: miR23b-3p (ID000400), miR23b-5p (ID243680_mat), miR24-3p (ID000402), miR24-5p (ID000488), miR27b-3p (ID000409), miR27b-5p (ID002174), snoRNA (ID001718), snoRNA202 (ID001232).

[0352] PCR

[0353] To assess the integrity of the Nnt transcript in BL / 6N and BL / 6J mice, PCR was performed using heart cDNA as previously described (Huang, TT et al., 2006, Hum Mol Genet, 15, 1187-1194).

[0354] Chromatin immunoprecipitation

[0355] ChIP analysis was performed using materials from the NRC according to the manufacturer's instructions and tested using the ChlP-IT kit (Active Motif) and analyzed by qRT-PCR. ChIP was performed with ChlP grade antibodies against HIF1α (mouse, ab1, Abeam). Computer promoter analysis and alignment were performed using Matlnspector and DiAlignTF (Genomatix). The primer sequences used for mir27b in ChIP were 5'-GCATGCTGATTTGTGACTTGAG-3' (SEQ ID NO 006) and 5'-CCTCTGTTCTCCAAACTGCAG-3' (SEQ ID NO 007).

[0356] MicroRNA microarray

[0357] MicroRNA microarray analysis was performed on three biological replicates of Vhl cKO mice and three control mice (Vhl fl / fl) and three biological replicates of TAC-operated Hif1αcKO mice and three TAC-operated control mice (TAC Hif1αfl / fl). Cardiac size and function of all mice were confirmed by echocardiography. Total RNA was isolated from the left ventricle and miRNAs were labeled using the miRCURY LNA microRNA Power Labeling Kit (Exiqon) and hybridized on miRNA arrays (miRXplore) with 1194 DNA oligonucleotides with reverse complement sequences of mature miRNAs. These arrays covered 728 human, 584 mouse, 426 rat, and 122 viral miRNAs, each of which appeared on the array in quadruplicate. Cy5-labeled miRNAs were normalized to a miRNA reference library that was also labeled with Cy3. All data are expressed as log ratios between diseased and control animals and deposited under GSE62418.

[0358] NADPH Quantification

[0359] 4 × 10 cells were seeded per well in a 3 cm culture dish. 5 Each NRC was determined and analyzed using the NADP / NADPH quantification kit (MAK038, Sigma) according to the manufacturer's recommendations. Data were normalized to the amount of protein in cell lysates obtained by Bradford analysis.

[0360] In vivo ATP quantification

[0361] ATP was separated and quantified with a linear gradient (0-1.5 M NaCl in 10 mM Tris-HCl, pH 8.0) on an anion exchange column (Nucleosil 4000-7PEI, 50 / 4 from Macherey-Nagel) using an HPLC system equipped with two independent UV-visible spectrometers (Shimadzu). The elution of the samples was monitored at 259 nm and 220 nm. Possible trace contaminants were detected using a wavelength of 220 nm.

[0362] ADP and ATP analysis

[0363] For ADP / ATP ratio analysis, 4 × 10 5 The NRCs were determined using the EnzyLight ADP / ATP ratio assay kit (ELDT-100, Bioassay Systems) as recommended by the manufacturer. For the quantification of ADP and ATP, EnzyLight TM ADP detection kit (EADP-100, BioAssay Systems) and EnzyLight ATP detection kit (EATP-100, BioAssay Systems). The signal is measured on a FLUOstar Omega plate reader (BMG). For ADP / ATP quantification in human and mouse heart tissue, the ADP / ATP ratio determination kit (ab65313, Abeam) recommended by the manufacturer was used for determination, with minor modifications. In brief, the heart tissue was frozen and stored in liquid nitrogen immediately after collection. The tissue was powdered with a mortar and suspended in lysis buffer (10 μl / mg tissue powder) at room temperature for 5 min. After centrifugation at 10000g for 1 min, the supernatant was used for analysis. The data was normalized to the amount of protein in the supernatant obtained by Bradford analysis.

[0364] ATP synthase activity assay

[0365] 4 × 10 5Cells were collected by trypsinization and then centrifuged at 1.2krpm for 5min. The particles were washed once with PBS (Invitrogen) and centrifuged at 1.2krpm for 5min. The particles were resuspended in 100μl PBS and frozen at -80°C, and the samples were prepared using an ATP synthase enzyme activity assay kit (ab109714, Abeam) as recommended by the manufacturer. The absorbance was measured at 340nm and 30°C for 3h at intervals of 1min using a FLUOstar Omega plate reader (BMG Labtech). ATP synthase activity was normalized to protein concentration.

[0366] Luciferase assay

[0367] 4×10 4 Each NRC was inoculated in a white 96-well plate and cultured for 3 days. 40 ng of wild-type or mutant pmirGLO Atp5a1 3'UTR construct was co-transfected with 6.25 nM, 12.5 nM or 25 nM control or miR27b mimics using Lipofectamine 2000 (Invitrogen) recommended by the manufacturer. 24 h after transfection, the activity of luciferase was determined on a FLUOstar Omega Microplate reader (BMGLabtech) using the dual luciferase reporter gene assay system (Promega) recommended by the manufacturer.

[0368] To evaluate the activity of the promoter, 20 ng of pGL3 vector was co-transfected with 1.25 ng of Renilla and 0-260 ng of HIF1α△ODD. At 36 h after transfection, the activity of luciferase was measured using the dual luciferase reporter gene assay system (Promega) recommended by the manufacturer. E2F transactivation activity was measured using the Cignal reporter gene assay kit (CCS-003L, Qiagen) according to the manufacturer's instructions using the dual luciferase reporter gene assay system (Promega).

[0369] Immunoblotting

[0370] Heart tissue was dissolved in blue wonder sample buffer (3.7M urea, 134.6mM Tris pH 6.8, 5.4% (v / v) sodium dodecyl sulfate (SDS), 2.3% (v / v) NP-40, 4.45% (v / v) p-mercaptoethanol, 4% (v / v) glycerol, 60mg / L bromophenol blue) and homogenized using an Ultra-Turrax T10 tissue homogenizer (IKA) to denature proteins at 95°C for 5min. NRCs were washed twice with ice-cold PBS and then collected in blue wonder sample buffer. Samples were sonicated using a Bransonic 5510 ultrasonic water bath (Branson) to reduce viscosity and boiled for 5min. After brief centrifugation, protein lysates were loaded onto 8% or 10% polyacrylamide microgels (Biorad) and then transferred to nitrocellulose membranes (GE Healthcare) by wet transfer. The membrane was blocked with TBST containing 5% (w / v) milk powder (Biorad), and then incubated with the primary antibody (the primary antibody was diluted with TBST containing 5% (w / v) bovine serum albumin (BSA)) at room temperature for 2 h or overnight at 4°C. After washing three times with TBST containing 5% (w / v) milk powder, the membrane was incubated with the appropriate HRP-conjugated secondary antibody (anti-goat IgG HRP, 61-1620; anti-mouse IgG HRP, 62-6520; anti-rabbit IgG HRP, 65-6120, Invitrogen) at a dilution of 1:5000 for 1-2 h. The membrane was then washed three times with TBST and chemiluminescence was detected with ECL (Amersham) on X-ray RX-NlF film (Fisher Scientific). Signal intensity was quantified by densitometry using Image J (version 1.47) (Schneider, CA et al., 2012, Nat Methods, 9, 671-675).The following antibodies were used for immunoblotting: anti-α-actin (A7811, Sigma), anti-ACC (3676, Cell Signaling), anti-phospho-ACC Ser79 (11818, Cell Signaling), anti-AMPKα (5832, Cell Signaling), anti-phospho-AMPKα Thr172 (2535, Cell Signaling), anti-Atp5a1 (ab14748, Abeam), anti-cardiac actin (61075, Progen Biotechnik), anti-Hif1α (NB100-479, Novus Biologicals), methylated lysine (dimethyl) (ab23366, Abeam), anti-Mthfd1l (ab116615, Abeam), anti-Rb (9309, Cell Signaling), anti-phospho-Rb Ser807 / 811 (8516, Cell Signaling), anti-Vhl (2738, Cell Signaling) and IgG isotype control antibody (ab171870).

[0371] Co-immunoprecipitation

[0372] For each condition, 0.5×10 7 Transfected (pEBG-AMPK 1-312 ) or transduced (HIF1α△ODD-lentivirus) NRC were lysed in TNN cell lysis buffer (50mM Tris-HCl pH 7.5, 250mM NaCl, 5mM EdTA, 0.5% NP-40, 50mM NaF, 0.5mM EGTA, 1mM PMSF, 1mM DTT and protease inhibitor cocktail) for 30min. Magnetic dynabeads (Invitrogen) were incubated with anti-AMPKα antibodies or IgG control antibodies (ab171870) for 10min at room temperature. AMPK was then immunoprecipitated from cell lysates by incubation with IgG control antibodies (ab171870) for 3h at 4°C. Finally, the reaction was terminated by boiling the beads in 6× Laemmli buffer for 5min. The samples were resolved in 10% SDS-PAGE and analyzed by Western blot using phosphorylated RbSer800 / 804 (Cell Signaling Technology) and phosphorylated AMPKαThr172 (Cell Signaling Technology).

[0373] Immunofluorescence staining

[0374] Immunofluorescence staining was performed as described previously (Krishnan, J. et al., 2009, Cell Metab, 9, 512-524). NRCs were fixed with 4% PFA / PBS, and then the cells were permeabilized and incubated with primary antibodies diluted in 2% (v / v) HS for 1 h at room temperature. After washing with PBS for 5 min for 3 times, the cells were incubated with 4'.6-diamidino-2-phenylindole (DAPI; D1306, Thermo Fisher Scientific, 0.1 μg / ml), phalloidin 555 (A34055, Molecular Probes), AlexaFluor 647 anti-mouse (A-11001, Thermo Fisher Scientific) and AlexaFluor 488 anti-mouse (A-21235, Thermo Fisher Scientific) secondary antibodies for 1 h at room temperature. For adult cardiomyocytes, slides were incubated with primary and secondary antibodies in a humidified chamber at 4°C overnight. The slides and dishes were mounted on slides (Fisher Scientific) with a drop of ProLongAntifade (Thermo Fisher Scientific). The slides / dishes were fixed with clear nail polish and then dried. The following primary antibodies were used: sarcomeric α-actin (A7811, SigmaAldrich), Ki67 (ab15580, Abeam), and phosphorylated histone H3 (Ser10) (05-817, Cell Signaling). Fluorescent images were obtained using an SP5 confocal microscope (Leica) at 20 times magnification. Cell size was blindly quantified using the software Image J (version 1.47).

[0375] Immunohistochemistry

[0376] Hearts were embedded in optimal cutting temperature (OCT) compound and sectioned at 10 μm. The sections were fixed with 4% PFA / PBS for 10 min, then blocked with 2% HS / PBS for 1 h at room temperature and washed twice with PBS for 2 min. After permeabilization with 0.2% Triton X-100 / PBS for 10 min, the sections were washed three times with PBS for 5 min, and then incubated overnight in a humidified chamber at 4°C with primary antibodies against sarcomeric α-actin (A7811, Sigma Aldrich, 1:800) and laminin (ab11575, Abeam, 1:300) diluted in 2% (v / v) HS. After washing with PBS for 10 min for 3 times, the sections were incubated with 4',6-diamidino-2-phenylindole (DAPI; D1306, Thermo Fisher Scientific, 0.1 μg / ml), AlexaFluor 555 anti-mouse (A-21422, Thermo Fisher Scientific, 1:500) and AlexaFluor488 anti-rabbit (A-11034, Thermo Fisher Scientific, 1:500) secondary antibodies at room temperature for 2 h. The sections were fixed with a drop of ProLongAntifade (Thermo Fisher Scientific), then fixed with clear nail polish and dried. Fluorescent images were obtained using an SP8 confocal microscope (Leica) at 20 times magnification. The entire z-axis was imaged and z-axis stacked images were generated with a step size of approximately 0.2 μm. To determine the number of nuclei per cardiomyocyte, the inventors used only cardiomyocytes cut along their longitudinal axis. Nuclei surrounded by the extracellular matrix stain laminin were excluded from the analysis. Quantification of nuclei was performed in a blinded manner.

[0377] Cryosections were stained with hematoxylin and eosin (H&E) or picrosirius red (Sigma). Slides were visualized using a Motic AE2000 with a Moticam 3 or an Axioscan.ZI slide scanner (Carl Zeiss).

[0378] [ 3 H]Leucine incorporation assay

[0379] [ 3 H]Leucine incorporation assay is used to measure de novo protein synthesis and can be used as an indirect readout of cell growth (Fukuzawa, J. et al., 2000, Hypertension, 35, 1191-1196). 4×10 5After 3 days, the cells were starved of serum overnight. The next day, the cells were cultured in medium without leucine for 4 h and then in medium containing labeled L-[4,5- 3 H(N)]isoleucine (specific activity of 30-60 Ci / mmol, ART0233, American radiolabeled chemicals) was cultured at a concentration of 0.5 μCi / mL for 20 h. The next day, the cells were washed with PBS, then trypsinized, and the radioactivity was measured in a liquid scintillation analyzer Tri-Carb2800TR (PerkinElmer) for 5 min. After trypsinization, cells were counted blindly using a Neubauer chamber, and the scintillation counts were normalized to the absolute cell number.

[0380] Nucleic acid incorporation analysis

[0381] 4 × 10 5 After 4 days, cells were starved of glucose for 1.5 h and serine or glycine for 3 h. For incorporation of radiolabeled glucose, cells were incubated in a 1 μCi / mL uniformly labeled [U- 14 C] glucose (specific activity 250-360 mCi / mmol, NEC042V250UC, Perkin Elmer) in glucose-free DMEM (Invitrogen) for 4 h. For the incorporation of radiolabeled serine, cardiomyocytes were incubated overnight in MEM (Invitrogen) supplemented with MEM vitamin solution (Invitrogen) and containing 0.6 Ci / mL of radiolabeled serine ([3- 14 C]serine, specific activity 50-62 mCi / mmol, NEC827050UC, Perkin Elmer). For incorporation of radiolabeled glycine, cells were incubated in a flask containing 1 μCi / mL uniformly radiolabeled glycine ([ 14 C (U)] glycine, specific activity> 100mCi / mmol, NEC276E250UC, Perkin Elmer) in BME (Invitrogen) for 4h. After washing the cells three times with PBS, the cells were collected in Trizol (Invitrogen) and nucleic acids were isolated according to the manufacturer's recommendations. The isolated nucleic acids were transferred to scintillation vials containing 4ml of liquid scintillation mixture Ultima Gold (Perkin Elmer) and the radioactivity was measured for 5min using a liquid scintillation analyzer Tri-Carb 2800TR (Perkin Elmer). The scintillation counts were normalized to the absolute nucleic acid amount.

[0382] Fatty acid oxidation

[0383] As previously described (Huynh, FK et al., 2014, Methods Enzymol, 542, 391-405), [1- 14 C]-palmitate (NEC075H, Perkin Elmer) was used to measure the fatty acid oxidation rate in animal tissues, except that each reaction used 0.7% BSA / 500 μM palmitate / 2 μCi 14 The radioactivity was measured for 5 min in a liquid scintillation analyzer Tri-Carb 2800TR (Perkin Elmer) with the exception of C-palmitate. The scintillation counts were normalized to the amount of protein.

[0384] Flow cytometry

[0385] 1×10 6 NRCs were seeded on 6 cm culture dishes (Nunc) and cells were collected by trypsinization after 4-6 days. The cells were washed once with PBS and centrifuged at 80g for 5min. The cells were resuspended in 500μL PBS and 5mL of cold 70% (v / v) ethanol (kept at -20°C) was immediately added. The fixed cells were kept at 4°C for up to 1 week. Before flow cytometric analysis, the cells were centrifuged and washed with PBS. After centrifugation at 80g for 5min, the cells were resuspended in 500μL propidium iodide solution (69μM propidium iodide in 38mM sodium citrate, pH 7.4) containing 40μg / mL RNase and incubated at 37°C for 1h. The samples were used on a flow cytometer ImageStream (Amnis), which was coupled to fluorescent image acquisition to obtain representative images of flow cytometric data. Multinucleation was quantified from ImageStream images.

[0386] Formate determination

[0387] 4 × 10 5cells and assayed using a formate assay kit (Sigma). The cells were washed twice with cold PBS and scraped and collected in 25 μL formate assay buffer. After centrifugation at 15,000 g for 5 min at 4°C, 20 μL of lysate was mixed with 5 μL formate assay buffer and added to a 96-well plate. 25 μL of reaction mixture (containing 23 μL formate assay buffer, 1 μL formate enzyme mixture, and 1 μL formate substrate mixture) was added to the plate containing the lysate. The samples were incubated at 37°C in the dark for 1 h, and the absorbance was measured at 450 nm using a FLUOstar Omega plate reader (BMG Labtech). The data were normalized to protein concentration.

[0388] Metabolomics

[0389] 4 × 10 5 NRC. After washing the cells with 75 mM ammonium carbonate (Sigma) and adjusting to pH 7.4 with acetic acid, the entire cell culture plate was quickly frozen in liquid nitrogen. Metabolites were extracted with cold extraction buffer (-20°C) (with a ratio of acetonitrile:methanol:water of 40:40:20). Metabolites were analyzed non-targeted by flow injection time-of-flight mass spectrometry as previously described (Fuhrer, T. et al., 2011, Anal Chem, 83, 7074-7080). Data were processed and analyzed using Matlab. Metabolomics analysis was performed using Metabolon as previously described (Cimen, I. et al., 2016, Sci Transl Med, 8, 358ra126) Fig.12 d).

[0390] Lipidomics

[0391] Mouse heart samples were homogenized on ice in ammonium bicarbonate buffer (150mM ammonium bicarbonate, pH 7) using an ultra-turax homogenizer. Protein content was determined using a BCA protein assay kit (Thermo Fisher). Equivalent 20 μg of protein was taken for mass spectrometry analysis. As previously described (Sampaio, JL et al., 2011, Proc Natl Acad Sci USA, 108, 1903-1907), lipid analysis based on mass spectrometry was performed using Lipotype GmbH (Dresden, Germany). Lipids were extracted by a two-step chloroform / methanol procedure (Ejsing, CS et al., 2009, Proc Natl Acad Sci USA, 106, 2136-2141). The samples were spiked with an in-house lipid standard mixture containing the following components: cardiolipin 16:1 / 15:0 / 15:0 / 15:0 (CL), ceramide 18:1;2 / 17:0 (Cer), hexosylceramide 18:1;2 / 12:0 (HexCer), lysophosphatidic acid 17:0 (LPA), lysophosphatidylcholine 12:0 (LPC), lysophosphatidylethanolamine 17:1 (LPE), lysophosphatidylglycerol 17:1 (LPG), lysophosphatidylinositol 17:1 (LPI), lysophosphatidylserine 17:1 (LPS), phosphatidic acid 17:0 / 17:0 ( PA), phosphatidylcholine 17:0 / 17:0 (PC), phosphatidylethanolamine 17:0 / 17:0 (PE), phosphatidylglycerol 17:0 / 17:0 (PG), phosphatidylinositol 16:0 / 16:0 (PI), phosphatidylserine 17:0 / 17:0 (PS), cholesterol ester 20:0 (CE), sphingomyelin 18:1;2 / 12:0;0 (SM), cholesterol D6 (Choi) (all Avanti polar lipids), triglycerides 17:0 / 17:0 / 17:0 (TAG) and diglycerides 17:0 / 17:0 (DAG) (all from Larodan Fine Chemicals). After extraction, the organic phase was transferred to an infusion plate and dried in a high-speed vacuum concentrator. The first dried extract was resuspended in 7.5 mM ammonium acetate (Sigma) in chloroform / methanol / propanol (1:2:4, V:V:V), and the second dried extract was resuspended in 33% ethanol in methylamine / chloroform / methanol (0.003:5:1, V:V:V) (all liquids were LC grade liquids obtained from VWR). All liquid handling steps were performed using a Hamilton Robotics STARlet robotic platform with anti-drip control for pipetting of organic solvents.

[0392] The samples were analyzed by direct infusion on a QExactive mass spectrometer (Thermo Scientific) equipped with a TriVersa NanoMate ion source (Advion Biosciences). In a single acquisition, the samples were analyzed in positive and negative ion modes with a resolution of Rm / z=200=280000 for MS and Rm / z=200=17500 for MSMS. MSMS was triggered by an inclusion list containing the corresponding MS mass range scanned in 1 Da increments. 119 . MS and MSMS data were combined to monitor CE, DAG, and TAG ions as ammonium adducts, PC, PC O- as acetate adducts, and CL, PA, PE, PE O-, PG, PI, and PS as deprotonated anions. MS only was used to monitor LPA, LPE, LPE O-, LPI, and LPS as deprotonated anions, Cer, HexCer, SM, LPC, and LPC O- as acetate adducts, and cholesterol as an ammonium adduct of the acetylated derivative.

[0393] Data were analyzed using LipidXplorer-based lipid identification software (Herzog, R. et al., 2012, PLoS One, 7, e29851) (Herzog, R. et al., 2011, Genome Biol, 12, R8). Data post-processing and normalization were performed using an in-house developed data management system. Only lipid identifications with a signal-to-noise ratio > 5 and a signal intensity 5 times higher than that of the corresponding blank sample were considered for further data analysis.

[0394] All downstream analyses were performed in R 123The results were performed on mole percentage transformed datasets, i.e. after converting the raw data (picomol) to mole percentages (each amount was divided by the sum of lipids detected in the respective sample and multiplied by 100). Principal component analysis (PCA) was calculated using the singular value decomposition function. The total carbon chain length and saturation plots were obtained by grouping together all lipids with the same number of carbon atoms (total length) or the same number of double bonds (saturation) and calculating their means and standard deviations in each sample cohort. The difference between the means of each class was calculated by subtracting the mean of the controls from the mean of the treated samples (treated minus reference), but only lipids with a difference greater than |0.3| are shown in the Supplementary Material. Significance was calculated by the nonparametric test Wilcoxon and p-values ​​were adjusted after Benjamini-Hochberg correction in case of multiple comparisons. Significance was set at p < 0.05. In addition to R-base functions, the following software packages were used: factoextra (Kassambara, A. & Mundt, F., 2017, factoextra: Extract and Visualize the Results of Multivariate Data Analyses), reshape2 (Wickham, H., 2017, Journal of Statistical Software, 21, 1-20), and ggplot2 (Wickham, H., 2009, ggplot2: Elegant Graphics for Data Analysis).

[0395] Bioinformatics analysis

[0396] Computer promoter analysis was performed using Matlnspector (Genomatix). Sequence alignment was performed using BLAST (http: / / www.ncbi.nlm.nih.gov / blast). shRNA was designed by a proprietary algorithm (targeted transgene), or shRNA was predicted by calculation using pSico Oligomaker (MIT, version 1.5) and BLOCK-iT RNAi Designer (Life Technologies). In order to predict the target of miR27b, miRWalk 2.0 database (http: / / mirwalk.uni-hd.de) was used, including many databases such as TargetScan, miRanda and RNA22 (Dweep et al., 2011, J Biomed Inform, 44, 839-847). Confocal images were quantified using Image J (version 1.47) (Schneider, CA et al., 2012, Nat Methods 9, 671-675).

Claims

1. Use of an oligonucleic acid agent capable of specifically inhibiting and / or degrading microRNA miR27b-5p in the preparation of a drug for treating or preventing heart disease, wherein the oligonucleic acid agent comprises or consists of a sequence as shown in SEQ ID NO 001; the heart disease is selected from hypertrophic cardiomyopathy, aortic stenosis and heart failure; The sequence shown in SEQ ID NO 001 is ACC AAT CAG CTA AGC T.

2. The use according to claim 1, wherein the oligonucleic acid agent is an antisense oligonucleotide.

3. The use according to claim 1, wherein the oligonucleic acid reagent comprises one or more locked nucleic acid (LNA) parts and / or peptide nucleic acid (PNA) parts.

4. The use according to claim 3, wherein the oligonucleic acid reagent comprises a locked nucleic acid (LNA) portion.

5. The use according to claim 3 or 4, wherein the locked nucleic acid (LNA) part is linked via a phosphorothioate bond. The use according to claim 1, wherein the oligonucleic acid reagent comprises 12-20 nucleotides.

7. The use according to claim 6, wherein the oligonucleic acid reagent comprises 14-16 nucleotides.

8. The use according to claim 1, wherein the oligonucleic acid reagent comprises or consists of a central block having 5-10 deoxyribonucleosides and flanked on both sides by 2'-O modified ribonucleotides or PNA oligomers.

9. The use according to claim 1, wherein the oligonucleic acid reagent comprises or consists of a central block having 5-10 deoxyribonucleosides and flanked on both sides by LNA nucleoside analogs.

10. The use according to claim 9, wherein the LNA nucleoside analogue is linked by a phosphorothioate moiety.

11. The use according to claim 1, wherein the oligonucleic acid reagent comprises or is substantially composed of the sequence shown in SEQ ID NO 005, wherein the sequence shown in SEQ ID NO 005 is ACCA-atcagcta-AGCT, wherein: Capital letters indicate nucleoside analogs. Lowercase letters represent DNA nucleosides linked by phosphates; and The linkage between nucleoside analogs and DNA nucleosides is achieved through phosphate and phosphorothioate.

12. The use as claimed in claim 11, wherein capital letters represent LNA.

13. The use according to claim 11, wherein the capital letters represent LNA linked via phosphorothioate.

14. The use according to claim 1, wherein the oligonucleic acid agent is attached to a nanoparticle, or encapsulated in a virus or lipid complex.

Citation Information

Patent Citations

  • Jet-and-suck blast nozzle with more air fountains

    CN1270091A

  • Composition for inhibition of expression of miR-27b, medicines containing the same, and use for the same

    CN102205124A

  • ANTI-miR-27b AND ANTI-miR-148a OLIGONUCLEOTIDES AS THERAPEUTIC TOOLS FOR TREATING DYSLIPIDEMIAS AND CARDIOVASCULAR DISEASES

    US20160138018A1

  • Chimera silver nanocluster probes for mirna detection

    WO2015007294A1